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Abstract - Novel nanoparticle drug delivery systems: application 
in the in vitro study of Bisnaphthalimidopropyl derivatives 
against human colorectal cancer cell lines. – submitted for the 
obtention of the degree of Master of Research by Mathieu Brunet. 
 
Colorectal cancer is one of the most severe causes of mortality worldwide 
accounting for 10% of total cancer cases. Although recent advances in early 
diagnosis have reduced the mortality rate associated with CRC, patients suffering 
from the later metastatic stage of the disease have a 5-year survival rate of only 
14%. To enhance the current treatment options, bisnaphthalimides (BNIPs) were 
developed as a new group of chemotherapeutic agents. Presenting promising 
results in vitro against colon cancer cell lines, these anti-cancer drugs are limited 
by a poor aqueous solubility and a dose-limiting toxicity. In recent years, 
nanoparticle drug delivery systems have been developed to enhance the 
solubility and the clinical response of encapsulated anti-cancer agents. In this 
study, the latest generation of BNIP derivatives including 
bisnaphthalimidopropyl-piperidylpropane (BNIPPiProp), bisnaphthalimidopropyl- 
ethylenedipiperidine (BNIPPiEth) and bisnaphthalimidopropyl 
diaminodicyclohexylmethane (BNIPDaCHM) have been studied against SW480 
and SW620 colorectal cancer cell lines. First, BNIPPiProp has been successfully 
encapsulated within solid lipid nanoparticles and a comparative cytotoxicity study 
was performed using MTT assay. After a 24-hour treatment, the 3 compounds 
alone demonstrated a strong cytotoxicity with IC50 values ranging from 1.3 to 2.6 
µM in both SW620 and SW480. However, the drug-free nanoparticle formulation 
was found to cause a high toxicity level. BNIP-treatments also led to a significant 
increase of ROS levels after a 24-hour treatment associated with an increase of 
DNA damage with the significant creation of DNA strand breaks against both cell 
lines (both at IC50). According to proteome profiler array, BNIPPiProp, BNIPPiEth 
and BNIPDaCHM were found to up-regulate and downregulate apoptosis-related 
proteins in a cell line and drug dependant manner. However, no increase in 
caspase-3 levels was detected after 24 hours against both cell lines using the 3 
compounds studied. Together, these findings demonstrate the relevance of BNIP 
derivatives in the treatment of colorectal cancer and offer a first-stepping stone 
in the design of a BNIP-drug delivery system.  
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1.1. Colon Cancer 
 
1.1.1. Overview of Colon Cancer 
 
The World Health Organization (WHO) has declared in their 2014 report that 
cancer represents one of the deadliest diseases worldwide estimating 14 million 
new cases in 2012. WHO has also projected that this disease caused 9.6 million 
deaths in 2018. After cardiovascular diseases, cancer is considered the leading 
cause of death worldwide (World cancer report, 2014). 
Cancer can be described as a heterogenous disease causing abnormal cell 
proliferation which can result in the formation of tumours. When this condition 
develops at the level of the colon or the rectum, it is then described as colon 
cancer or colorectal cancer (CRC). This subtype of cancer is one of the most 
diagnosed worldwide with more than 2 million cases reported every year (Stewart 
and Kleihues, 2003). More than 50% of the total number of cases are found in 
developed western countries, however, it has spread in numerous developing 
countries in recent years making it a major global challenge (Brody, 2015). A 
number of risk factors increase the likelihood of developing CRC, with age, diet, 
physical activity and the presence of additional bowel-related conditions being 
the most prevalent factors (John and Houlston, 2001; Haggar and Boushey, 
2009). 
CRC mortality has been reduced with the use of early diagnosis and with the 
development of screening programs which have offered a greater survival rate 
to patients responding more positively to the available treatments (Moiel, 2011). 
Moreover, the number of treatment options has increased in the recent years 
with the development of innovative strategies and the improvement of existing 
therapies. Nevertheless, only 1 in 10 patients survive the metastatic form of CRC 






1.1.2. Pathophysiology of colon cancer 
 
CRC precursors are benign neoplasms or serrated polyps which correspond to 
the development of small cell clumps on the external surface of the colon 
epithelium (Ionov et al., 1993). Over many years, local inflammatory changes or 
endogenous genetic modifications can cause the polyp to slowly become 
cancerous. Epigenetic and genetic mutations account for 70% of CRC cases. The 
loss of genomic stability represents a central event, initiating the development 
of CRC (Grady and Carethers, 2008). The sequential progression of CRC from 
benign polyp to metastatic cancer has been divided into 5 stages. These stages 
have many subtypes based on criteria of the TNM (Tumour / Node / Metastasis) 
staging system which indicate the progress of the disease in the tissue or in the 
entire body (figure 1) (Cunningham et al., 2010). Figure 1 presents the different 
stages of CRC with stage 0 being the benign presence of a polyp to stage 4 when 




Figure 1. Representation of the staging evolution of CRC (Terese 




The pathogenesis of CRC originates with the generation of genetic mutations, 
which can be inherited and shared in the family, or acquired. The resulting 
genetic or epigenetic alterations disrupt the genomic stability creating malignant 
cells (Pino and Chung, 2010). In the case of inherited mutations, genes such as 
LH1, APC, MSH2 and PMS2 can be altered but account for only 5% of CRC cases 
(Kinzler and Vogelstein, 1996). Acquired mutations generally generate a cascade 
of genetic alterations leading to a chromosomal instability. The apparition of the 
cancerous phenotype is mostly due to the alteration of the APC, KRAS or p53 
genes (Simon, 2016). APC is linked to the cell division processes and code for a 
transcription factor involved in the regulation of oncogenes. KRAS is an oncogene 
involved in cell growth and differentiation whereas p53 is related to apoptosis 
initiation. Therefore, the alteration of these genes can create the conditions of 
tumour growth. Other tumour suppressor genes such as PTEN, TP53 or MLH1, 
MSH2 and MSH6 also take part in the pathophysiology of colon cancer when 
inactivated (Markowitz and Betagnolli, 2009). Alternatively, aberrant DNA 
methylation or DNA repair defects can also be responsible for the genomic 
instability (Ashktorab and Brim, 2014). Moreover, if they are not directly involved 
with CRC pathogenesis, several genes have been found to be involved in the 
disease development via the disruption of key cellular pathways including WNT 
or TGF-β. 
Nowadays, a 90%-survival rate is reported when patients are diagnosed with 
CRC stages I and II. However, if the cancer is not diagnosed before reaching the 
metastatic late-stage, a survival rate of 13% is then reported (KMA Cancer 
Committee, 2005). The continuous improvement of the understanding of CRC 
pathophysiology at the molecular level has allowed advances in the design of 
diagnostic tools and therapy. Nevertheless, the advanced stages on CRC remain 








1.1.3. Current therapeutic approaches 
 
Treatment options are available for patients suffering from CRC and the 
therapeutic approach is decided upon various factors including CRC stage, the 
age and health status of the patient, and the analysis of the tumour 
characteristics (size and location). The correct staging of CRC involves the use of 
colonoscopy combined with a biopsy to obtain a precise diagnosis when possible, 
however, imaging techniques such as computerised tomography scans and 
magnetic resonance imaging are also employed (Barret et al., 2013). 
One of the main treatment options offered remains surgery with the removal of 
the primary tumour using the complete mesocolic excision procedure or 
polypectomy (Hohenberger et al., 2009). Surgery is often the chosen procedure 
at stage I/II of CRC. Alternatively, for high risk stage II CRC, radiotherapy can 
also be employed as an adjuvant to eliminate cancerous cells using high energy 
X-ray (Castaneda and Strasser, 2017). Moreover, adjuvant chemotherapy can 
also be used to reduce the tumour mass and control cancer progression and avoid 
recurrence.  
From stage III, chemotherapy is the treatment of choice and it is based on the 
use of cytotoxic compounds eliminating malignant cells (Aydinlik et al., 2016). 
For CRC, effective chemotherapy began with the development of 5-fluorouracil 
(5-FU) in the late 1950s (Heildelberger et al., 1957). This compound inhibits 
tumour growth by inhibiting cancer cell proliferation (inhibitor of thymidylate 
synthase). Alternative compounds such as oxaliplatin (DNA replication inhibitor) 
or irinotecan (topoisomerase I inhibitor) can act synergistically with 5-FU 
resulting in more positive outcomes for patients (Yildiz et al., 2018). However, 
these anti-cancer drugs have presented serious side effects such as organ 
toxicities as their action is not specific to malignant cells. Moreover, after 
exposure to chemotherapy, cancer cells can develop a resistance to the 
mechanism of action of the drug used also known as chemoresistance (Yeldag et 
al., 2018). To mitigate these limitations, clinicians have to lower the dosage, 
thus, reducing the efficacy of the treatment and decreasing the survival rate in 
patients (Laura et al., 2015). For late metastatic CRC, the low 5-year survival 
rate demonstrates the need for new therapeutic options.  
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For the last twenty years, researchers and clinicians have been trying to enhance 
current available chemotherapy and to identify new molecular targets for the 
treatment of CRC. Nowadays, the backbone of CRC treatment remains the 
combination of fluorouracil with a second anti-cancer drug with for example 
irinotecan (FOLFIRI) or oxaliplatin (FOLFOX) (Díaz-Rubio et al., 2007; Guo et al., 
2016). Among the most innovative strategies, the use of monoclonal antibodies 
has been explored. These antibodies such as cetuximab and panitumumab target 
endothelial growth factor (EGF) and the associated EGF receptor (R) (Jonker et 
al., 2007; Amado et al. 2008). EGFR is a CRC prognostic factor and its expression 
is linked to initiate events such KRAS mutation. These antibodies can either bind 
to EGFR (panitumumab) and provoke the receptor’s internalisation or act as a 
competitive ligand preventing other molecules to activate EGF signalling 
pathways (de Mello et al., 2013). Alternative targets have also been studied, for 
example the use of bevacizumab to inhibit angiogenesis. Moreover, the addition 
of these antibodies to the pre-existing combination chemotherapy has 
demonstrated better tolerated toxicities and increase survival outcome in 
patients. 
However, even combination therapy including the monoclonal antibodies leads to 
adverse effects such as skin rash, hypomagnesemia and nausea (Monti et al., 
2007). As 25% of patients diagnosed already experience advance CRC (stage 4), 
the development of new drugs and potentially new targets is necessary to 
achieve the clinical translation of augmented therapies, to overcome the current 
treatment limitations and the increase of chemoresistance (Huang and Sadee, 
2006). 
In this project, a promising family of chemotherapeutic agents developed at the 








1.2. The BNIP derivatives, a promising family of 
chemotherapeutic agents 
 
1.2.1. The history of the BNIPs 
 
The history of naphthalimide compounds started in the 1970s when they were 
reported to be initially synthesised (Chen et al., 1993). Naphthalimide (figure 2) 
is comprised of three six-membered rings and has demonstrated its potential as 
a chemotherapy agent presenting a strong anti-cancer activity (Brana et al., 
2001; Ralton et al., 2007). Interestingly, naphthalimide compounds have intense 
UV and fluorescent properties which led to their use in a range of other 
applications such as fluoride ion sensors or fluorescent tracers (Xu et al., 2005; 
Stewart, 1978). 
Structurally, naphthalimides have a flat aromatic structure which have been 
linked to their ability to bind with DNA by intercalation. Moreover, the presence 
of a basic terminal group on its side chain is essential to its anti-cancer properties 
as a decrease of basicity in this group was shown to lower the drug cytotoxicity 
(Kamal et al., 2013).  
Figure 2. Representation of the chemical structure of naphthalimide. 
 
The design of this compound is comprised of shared structural similarities with 
other chemotherapy agents such as cycloheximide or CG-630 (Brana et al., 
2001). After the synthesis of the naphthalimide monomer, Brana and Ramos 
(2001) attempted variations of the side chain and of the aromatic ring to enhance 
its activity. Interestingly, oxygen and sulphur atoms were found to decrease the 
molecule’s activity.  
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Among all the derivatives developed by Brana et al. (2001), mitonafide and 
amonafide were screened and selected by the National Cancer Institute (USA) as 
the more potent compounds. After an extensive in vitro study against leukaemia 
and cervical cancer, the inhibition of topoisomerase II was presented as their 
anti-cancer mechanism of action. Moreover, based on their strong anti-cancer 
activity, these two drugs reached Phase I and II clinical trials (Leaf et al., 1997; 
Cassado et al., 1996). Unfortunately, central nervous system toxicity leading to 
dementia was reported with the use of mitonafide whereas important 
myelosuppression was reported with the use of amonafide (Alami et al., 2007). 
These early clinical trials showed the potential of naphthalimide as 
chemotherapeutic agents. Nevertheless, the existence of a dose-limiting toxicity 
was still a critical limiting factor (Brana et al., 2001). 
To augment the therapeutic efficacy of the naphthalimide, Brana et al. (2003) 
developed an innovative symmetrical compound associating two naphthalimide 
groups together and were named bisnaphthalimides. The union of the two 
naphthalimido rings was performed using a polyamine-type linker chain. The in 
vitro study of bisnaphthalimides against colon HT-29 cells showed an increased 
cytotoxicity compared to the previous generation of BNIPs. Additionally, it was 
observed that the length of the chain and its alterations were linked to the 
resulting cytotoxicity of the compound.  
Bisnafide and Elinafide reached clinical trial Phases I and II, however side effects 
such as neuromuscular toxicity remained. Subsequent formulation improvements 
focused on the design of the linker chain to overcome the current limitations of 
this family of compounds including a poor aqueous solubility and a dose-limiting 
toxicity. 
The use of polyamines has proven to be a key discovery in the formulation of 
BNIPs improving both their in vivo and in vitro activities. Kong Thoo Lin and 
Pavlov (2000) created a new generation of BNIPs involving the use of natural 
polyamines with a variation in the length of the chain and the number of 
heteroatoms. Bis-naphthalimidopropyl putrescine (BNIPPut), spermidine 
(BNIPSpd), spermine (BNIPSpm) and oxaputrescine (BNIPOPut) were 
synthesised and studied in vitro (Kong Thoo Lin and Pavlov, 2000). Their study 
concluded that the presence of heteroatoms in the linker chain improved the 
9 
 
drugs’ aqueous solubility whereas the increased length of the linker chain 
decreased the drugs’ cytotoxicity level. Interestingly, Brana et al. (2005) also 
demonstrated that the symmetrical structure of the linker chain was associated 
with the resulting cytotoxicity (Brana et al., 2005).  
The development of BNIPs with the optimisation of their linker chain was 
continued by Barron et al. (2010) which reported that the addition of cyclohexane 
rings or nitrogen atoms in the linker chain augments the cytotoxic activity of the 
compound. From this work, bisnaphthalimidopropyl diaminodicyclohexylmethane 
(BNIPDaCHM) was studied in vitro against breast cancer cells (human breast 
epithelial MDA-MB-231) and exhibited a stronger cytotoxic activity (IC50 < 5 µM 
after 24 h treatment) than the anti-cancer agent doxorubicin. Further 
investigations revealed that BNIPDaCHM induces DNA double strand breaks and 
an inhibition of DNA repair against human breast adenocarcinoma cell line (MDA-
MB-231). This new information led to a better understanding of their mechanism 
of action (Barron et al., 2010). However, many questions remained unanswered 
regarding further improvement of the formulation and the mechanism of action 
of this family of compounds depending on the type of cancer targeted. 
 
1.2.2. The last generation of BNIP derivatives 
 
Based on the promising results obtained with BNIPDaCHM, Kopsida et al. (2016) 
synthesised the most recent generation of BNIPs using the latter as a parental 
compound to investigate if the ring position and the length of linker chain could 
augment the cytotoxic and DNA-binding properties of BNIPs. Therefore, 
bisnaphthalimidopropyl-piperidylpropane (BNIPPiProp) and 
bisnaphthalimidopropylethylenedipiperidine dihydrobromide (BNIPPiEth) were 







Figure 3. Representation of BNIPPiProp, BNIPPiEth and BNIPDaCHM 
chemical structures (adapted from Kopsida et al., 2016). 
 
BNIPPiProp is a structural isomer of BNIPDaCHM whereas BNIPPiEth is an isoform 
of BNIPPiProp having one less carbon at the centre of the linker chain. The 
resulting 3 compounds were studied in vitro in human breast cancer cells. 
BNIPPiEth was reported as the most cytotoxic compound against MDA-MB-231 
and SKBR-3 cells (IC50 values ranging 0.2-3.3 µM) suggesting that the shorter 
linker chain enhanced its cytotoxicity (Kopsida et al., 2016). 
The main barriers between the BNIPs and their use as a chemotherapeutic agent 
are their poor aqueous solubility and achieving a targeted delivery. To overcome 
these limitations, this project will study the use of nanoparticles as a delivery 








1.3. Nanoparticles as delivery systems for anti-cancer agents 
 
The term nanoparticle was coined during the 1960s with the first formulation of 
lipid-based nanoparticles reported by Shlunk and Lombardi in 1969. 
Nanoparticles correspond to objects having a size ranging from 1 to 1,000 nm 
(Shlunk and Lombardi, 1969). A wide range of nanoparticle formulations exist 
and can be used in different fields, however, most of them are designed to treat 
or diagnose different diseases. Several medical applications are currently used: 
in bioimaging, with novel nanoparticle-based contrast product for MRI, or in 
biosensing with the detection of cancer biomarkers (Wilczewska et al., 2012). 
However, the main use of nanoparticles is as drug carriers with the encapsulation 
of therapeutic molecules such as anti-cancer agents. 
 
1.3.1. The benefits of nanoparticles in a drug delivery system 
 
Using nanoparticles as a drug carrier is beneficial on two levels. First, the use of 
a drug carrier has a protective function for the encapsulated drug permitting its 
transport as well as limiting its premature degradation in vivo (Sagar et al., 
2011). The drug can be protected from being damaged by its environment 
including biological barriers such as the mononuclear phagocyte system (MPS) 
(Blanco et al., 2016). The encapsulation within a nanoparticle drug delivery 
system can also improve the drug’s intrinsic physicochemical properties with for 
example the sustained and controlled release of the drug and the reduction of its 
systemic toxicity (Aleksandrowicz et al., 2017).  
Being administered in the human body mostly via the intravenous administration 
route, the aqueous solubility of the drug is often a challenge. Arriving in the blood 
stream, sequential obstacles are presented to the anti-cancer agents limiting 
their action (Ferrari, 2010). Resident macrophages from the MPS can uptake the 
circulating drug and the non-specificity of free drug can result in the potential 
accumulation of the drug in healthy organs such as the spleen or the liver. Even 
when the drug has reached the tumour site, the tumour microenvironment can 
be challenging and the cellular internalisation can be uncertain due to the 
endosomal escape (Li et al., 2020). 
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One of the most interesting aspects of the use of nanoparticles as drug carriers 
is the possibility of actively or passively targeting a specific organ, tissue or cell 
type and thus overcoming the issues associated with non-specific delivery. The 
active targeting corresponds to the addition of molecules such as antibodies, 
aptamers or peptides at the surface of the drug carrier allowing the nanoparticles 
to bind to a specific target such as a malignant cell (Acharya and Sahoo, 2011). 
With active targeting, treatment efficiency can be increased, and side effects can 
be prevented as the ligands improve the binding of drug carriers to the targeted 
cells, and therefore, enhance their cellular uptake in targeted cancer cells and 
not in healthy cells (Yoo et al., 2019). However active targeting presents 
important limitations as this approach does not represent a guiding system for 
the nanoparticle but an enhancer to its specific cell-binding properties which does 
not improve large-scale distribution in the body (Choi et al., 2009). Moreover, 
the cost of the development of such a system needs to be considered as high 
specificity ligands can be very expensive and can be a limiting-factor in the design 
of large-scale production (Cheng et al., 2012). 
Importantly, nanoparticles can also undertake passive targeting which is 
particularly interesting in cancer therapy. Once a tumour has reached a diameter 
of a few millimetres, it will need to build a nutrient supply network via 
angiogenesis (Baban and Seymour, 1998) which is triggered by the tumour itself. 
The lack of O2 triggers the production of growth factors which, in turn, induce the 
formation of blood capillaries. These capillaries can link to the original blood 
system; however, they present irregularities in their structure such as weak 
inter-cellular epithelial junctions and high levels of membrane channels (Pope 
Harman et al., 2007). The nanoparticles take advantage of these cancer 
specificities and passively accumulate in the tumour due to their nano-size (> 
200 nm) which allow them to cross the epithelial junctions. This phenomenon is 
also called the EPR (Enhanced Permeation and Retention) effect as presented in 




Figure 4. Representation of the enhanced permeability and retention 
(EPR) effect associated with the use of anti-cancer drug delivery 
systems (Bae et al., 2011). 
 
The EPR effect is responsible for the passive targeting of the nanoparticles and it 
is based on the small size of the delivery system making the treatment cancer 
specific. However, it is critical to reflect on the EPR-based cancer therapy design 
as the understanding of EPR effect has evolved since its first description in 1986 
by Matsumura and Maeda (Matsumura and Maeda, 1986). During the last 10 
years, several studies showed that the EPR effect was heterogenous depending 
on the stage of the tumour development and on the tumour type which can lead 
to bias in pre-clinical studies for the development of nanomedicines (Tanaka et 
al., 2017; Golombek et al., 2018). 
Therefore, the use of nanoparticles as a drug delivery system presents numerous 
advantages for the facilitated delivery of anti-cancer drugs while reducing the 
associated drug side effects. Although these benefits are shared by all nano-drug 
delivery systems, each type of nanoparticle has specific properties which need to 




1.3.2. Types of nanoparticles 
 
Despite its youth, the nanomedicine field has expanded rapidly in recent years 
with the development of a large variety of nanotechnological platforms (figure 
5). Nanoparticles can be split into two categories: the organic nanoparticles, 
including the polymeric and lipid nanoparticles, and the inorganic nanoparticles. 
The latter are metal-based formulations (mostly iron- and gold-based) with 
interesting optical and magnetic properties. These particles have been widely 
investigated as drug carriers allowing a high drug loading capacity and an ease 
to functionalise their external surface. Among successful examples, mesoporous 
silica, gold, iron and copper-derived nanoparticles can be mentioned (Hu et al., 
2013; Bobo et al., 2016). Moreover, this class of nanoparticles is used for specific 
bioimaging techniques such as iron oxide nanoparticles in MRI (Chertok et al., 
2008). Interestingly, the combination of diagnostic and therapeutic approaches 
is called the theranostic strategy when the drug delivery system can 
simultaneously be used as an imaging agent (Yang et al., 2011). Nevertheless, 
these inorganic nanoparticles are limited by safety issues associated with their 
low biocompatibility and the lack of knowledge regarding their long-term 
cytotoxicity (Laurent et al., 2008).  
To obtain greater biocompatibility, organic nanoparticles have been designed as 
drug carriers. The encapsulated molecule of interest can be DNA, proteins or 
drugs (Jong and Borm, 2008). Within the organic class of nanoparticles, the 
polymeric and lipid-based formulations are distinguished by the nature of their 











Figure 5. Schematic representation of the structure of the most common 
types of nanoparticle drug delivery systems (created using 
BioRender™). 
 
Regarding polymeric nanoparticles, they are made of repeated subunits and 
chains of polymers and can be used to entrap or be conjugated to a drug of 
interest. Polymers such as chitosan, albumin or heparin have been extensively 
used for the delivery of nucleic acids, proteins or drugs. For example, the 
abraxane formulation has been developed to encapsulate the anti-cancer drug 
paclitaxel within polymeric nanoparticles composed of albumin. Since, it has been 
used clinically for the treatment of metastatic cancer (William et al., 2005). 
Moreover, the use of biodegradable polymers such as polyethylene glycol (PEG) 
or poly-l-glutamic acid (PGA) have also been employed to enhance the anti-
cancer efficacy of a multitude of drugs including camptothecin (Sabbatini et al., 
2004; Bhatt et al., 2003). Alternatively, the development of polymeric micelles 
(also called amphiphilic block copolymers) and dendrimers have been reported 
as promising resources. Polymeric micelles are composed of a hydrophobic core 
containing the therapeutic agent of interest with a hydrophilic polymeric shell 
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whereas dendrimers are nanoparticles exhibiting branches of monomers around 
a central core (Cho et al., 2008). Both technologies have shown promising results 
with, for example, the conjugation of cisplatin with dendrimer (Malik et al., 1999) 
or (PEG-poly(D,L-lactide)-paclitaxel which is a polymeric micelle formulation of 
paclitaxel that reached clinical trial phase I (Kim et al., 2004). The main 
advantage of using polymeric nano-formulations is that they can be designed as 
tailored-nanomedicines with reproducible and predictable properties. However, 
all polymeric nanoparticles are not biocompatible and their production can 
require the use of organic solvents which are toxic for patients (Chan et al., 
2010).  
To overcome these limitations, lipid-based formulation of nanoparticles has been 
designed. They do not require the utilisation of hazardous organic solvents in 
their production and the use of lipids offer a great biocompatibility and 
degradation capacity in vivo. The first lipid-based formulation created was the 
liposome in 1965 and is still the most extensively studied and used lipid-based 
drug delivery system today (Bangham, 1993). With more than 10 liposomal 
products clinically approved, these self-assembling nanoparticles harbouring a 
lipid-bilayer membrane are formidable carriers of hydrophilic agents (Torchilin, 
2005).  
To deliver lipophilic compounds such as BNIPs, other lipid-based systems named 
solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) have 
become very popular due to their versatility (figure 6) (Talegaonkar and 
Bhattacharyya, 2019). The formulation of SLNs was first introduced by Müller in 
1993 whereas NLCs appeared a decade after (Müller et al., 1993). Both 
formulations are nanoparticles formed by a lipid core, however SLNs have a solid 
lipid core instead of the liquid lipid core found in NLCs. The creation of SLNs 
revealed that these nanoparticles presented several advantages including the 
protection of the encapsulated molecule against environment degradation, the 
increase bioavailability of hydrophobic molecules, the low cost and ease of 
production and the absence of organic solvent in their preparation (Das and 




Figure 6. Schematic representation of SLNs and NLCs (Subramaniam et 
al., 2020). 
 
SLNs are mainly composed of lipids and surfactants, and the choice of each is 
critical for the resulting nanoparticles’ properties. All components chosen are 
preferably of GRAS (Generally Recognized As Safe) or approved by the U.S. Food 
and Drug Administration (FDA). The lipid is the major component of the 
nanoparticle matrix, making the type of lipid chosen very important. Most of the 
lipids used are fatty acids such as stearic acid (Severino et al., 2011), 
triglycerides such as tricaprin (Lim and Kim, 2002) or waxes such as cetyl 
palmitate (Farboud et al., 2011). Stearic acid is a natural lipid found ubiquitously 
which is safe and biodegradable (Gonzalez-Mira et al., 2010). Stearic acid has 
also demonstrated the specific ability to accumulate in the cytoplasm of cancer 
cells making it ideal to transport BNIP compounds (Severino et al., 2011). Other 
derivatives such as palmitic or oleic acids can be chosen alternatively or in 
combination, as the crystallinity of the lipid core can enhance the drug loading 
capacity (Bavani et al., 2020). 
The surfactant is the second major SLN component and it is used as a stabilising 
agent, essential to obtain a good dispersion of the nanoparticles when the lipid 
and aqueous phases are mixed. It is also responsible for the stability of the nano-
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structure during storage, and for maintaining the shape and the dispersion of the 
SLNs in vivo (Mehnert and Mäder, 2001). A surfactant can be cationic, anionic, 
non-ionic or amphoteric depending on the design of the nanoparticles to maintain 
a good hydrophile-lipophile balance. Tween 80 and Poloxamer 188 appear to be 
the most widely used stabilising agents and a combination of surfactants is 
usually chosen (Leonardi et al., 2014). In this project, Tween 80 and Span 20 
were the two non-anionic surfactants used as stabilisers chosen for their known 
biocompatibility and extensive use in the formulation of SLNs. The phospholipid 
egg lecithin was also present due to its emulsifying capacity as amphoteric 
surfactant. 
Regarding their production method, SLNs are mostly produced through the hot 
homogenisation method which consists of the dispersion of the melted lipid phase 
in an aqueous phase containing surfactant (Schwarz et al., 1994). Subsequently, 
the mix is homogenised at high speed, maintaining the emulsion at a 
temperature greater than the lipids’ melting points. The resulting nanoparticles 
in suspension are then cooled down to form solid matrices. An alternative 
technique, the cold homogenisation, can also be used when lipophobic or 
thermosensitive drugs are employed. Nevertheless, this method has 
demonstrated the creation of more polydispersed and larger particles (Mehnert 
and Mäder, 2001). 
Determining the ideal formulation of a nanoparticle will depend on the 
encapsulated molecule but also on the chemical property requirements such as 
release rate, storage time and hydrophobicity. For example, the lipase enzymes 
can degrade lipids by splitting their ester linkage and it has been shown in vitro 
that the velocity of this degradation depends on the lipid matrix and surfactant 
composition which can be critical for the targeted biodistribution of SLNs (Yang 
et al., 1999). 
Although thousands of formulations have been reported, only a few have been 
approved by the FDA. This is partly due to the fact that for most compounds, the 
nanoencapsulation demonstrated a small potency increase, which is not sufficient 




Many solid lipid nanoparticle delivery systems have been reported to encapsulate 
anti-cancer drugs successfully such as paclitaxel (Lee et al., 2007), camptothecin 
(Yang and Zhu, 2002) or doxorubicin (Wong et al., 2006). In these cases, the 
use of nanoparticles as a delivery system has increased the anti-cancer activity 
of the SLN-encapsulated drug compared to the free drug showing promising 
results for the SLN-encapsulation of BNIP derivatives.  
To obtain similar results with an increased anti-cancer activity from the BNIPs, 
their poor aqueous solubility must be addressed. Tetrandrine and Emodin, two 
anti-cancer agents, shared the same limitation. However, both drugs have been 
successfully encapsulated into lipid nanoparticles, making the use of SLNs a 
promising approach to address the hydrophobicity of BNIPs (Wang et al., 2012; 
Li et al., 2011). Adapting nanotechnology to the BNIPs is an idea that researchers 
have already explored: BNIPs has been encapsulated into Poly Lactic Acid (PLA) 
and Poly Lactic-co-Glycolic Acid (PGLA) polymeric nanoparticles against 
Leishmania infantum (Costa Lima et al., 2012). However, BNIPs encapsulation 
into lipid nanoparticles to treat colon cancer has not been studied yet. 
In addition to the development of a drug delivery system, understanding the 
mechanism of action of an anti-cancer drug and its cellular fate is key in 
developing tailored nanomaterials and this can be studied in a synergistic way to 
achieve faster clinical translation.  
 
1.4. The evaluation of the impact of the BNIPs on their 
efficacy as anti-cancer agents 
 
1.4.1. SW480 and SW620 as in vitro model for colon cancer 
 
For this project SW480 and SW620 were the two cell lines used to study CRC in 
vitro. Used worldwide, these two colon carcinoma cell lines offer a unique 
platform for CRC research as they were derived from the same patient, at two 
different stages of his CRC. Therefore, they offer an interesting alternative to 
non-metastatic CRC cell lines such as CaCo-2 or HT-29 which are employed most 
of the time.  
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SW480 cells were derived from a 50-year old patient at an early stage from 
primary tumours whereas SW620 cells were derived 6-month later when 
mesenteric lymph node metastases were discovered (Rober et al., 2000). 
Deriving from the same individual, these two cell lines shares the same genetic 
background allowing a more precise in vitro analysis of the phenotypic differences 
between the early and late stage of CRC as confirmed by the study of their 
chromosomal markers (Melcher et al., 1995).  
Although this in vitro model has already been used to study SLNs-encapsulated 





Apoptosis is a naturally-occurring cellular mechanism also known as programmed 
cell death. In healthy humans, apoptosis is a critical process involved in tissue 
development and cellular homeostasis via the regulation of the balance between 
cell death and cell proliferation (Claire et al., 2018). Opposed to apoptosis, 
necrosis can be described as accidental cell death due to tissue damage 
provoking the lysis of the cells in the surrounding environment leading to 
inflammation. On the other hand, apoptosis is a highly regulated and 
sophisticated mechanism involving the fragmentation of the cellular content 
within membrane vesicles to be phagocytosed, therefore preventing an 
inflammatory reaction (Elmore, 2007).  
For programmed cell death to be activated, specific conditions including DNA 
damage or abnormal cell growth must trigger one of the two cellular apoptotic 
pathways (Lopez and Tait, 2015). They are known as the intrinsic and extrinsic 
pathways or, respectively, mitochondrial and death receptor pathways. These 
two different routes are separated upon on the nature of the triggering signal. 
Both pathways converge at a common end-point being the activation of the 
caspases (cysteine aspartyl-specific proteases) cascade (figure 7) (Julien and 
Wells, 2017).  
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First, with the intrinsic pathway, internal stimuli such as DNA damage, 
biochemical stress, the lack of growth factors, oxidants or microtubule targeting 
drugs will induce the activation of mitochondrial proteins such as Bcl-2 or Bax, 
which are pro-apoptotic proteins bound to the mitochondria membrane (Zaman 
et al., 2014). The resulting disruptions of the mitochondrial membrane then lead 
to the release of the cytochrome c in the cytoplasm. It will then form a complex 
with the protein APAF1 called the apoptosome, which activates the initiator 
caspase-9 leading to the activation of the caspase cascade. 
On the other hand, the extrinsic pathway relies on specific extracellular signalling 
to be activated also known as cell death ligands (Goldar et al., 2015). Once 
attached to death receptors such as Fas (CD95), TNF (TNFR1) or TRAIL, the 
activation of the formed complex then initiates the recruitment of adaptor 
proteins such as Fas-associated death domain (FADD) and TNF receptor-
associated death domain (TRADD) (Goldar et al., 2015). Subsequently, the 
death-inducing signalling complex (DISC) is then created via the association of 
initiator procaspase 8 and 10 to the adaptors. Once formed, DISC can then 
activate the caspase cascade through the activation of procaspase 8 and 10 
(Karp, 2008).  
The activation of caspase 9 (intrinsic pathway) or caspase 8 (extrinsic pathway) 
results in the activation of caspase 3. From that event, the last stage of apoptosis 
initiation begins and is known as the execution pathway (D’Arcy, 2019). Caspases 
are the key mediators of apoptosis as they are responsible for the dismantlement 
of the cell through the cleavage of a large number of proteins (Lopez and Tait, 
2015). Within this family of proteins, caspases 2, 8, 9 and 10 are known as 
initiator caspases whereas caspases 3, 6 and 7 are the executioner caspases. In 
both pathways, when an initiator caspase is activated, it then leads to the 
activation of effector caspases by proteolytic cleavage. The execution pathway 
results in the activation of endonucleases and proteases for the degradation of 
the cell cytoskeleton and chromosomes. Cells then organise their 
compartmentalisation with the creation of apoptotic bodies which can be 
eliminated through phagocytosis protecting the cellular environment from 





Figure 7. Representation of the intrinsic and extrinsic pathway of 
programmed cell death (Elisabeth et al., 2006). Green arrow = activation / 
Black arrow = inhibition 
Discovered by Kerr et al. (1972), the apoptotic mode of cell death has been 
studied extensively targeting its induction for treating diseases. Drugs, such as 
navitoclax which inhibits apoptotic inhibitors (Bcl-2 family) leads to an increased 
programmed cell death (Olsterdorf et al., 2005). These strategies are used in the 
fight against cancer making the enhancement of apoptosis levels a therapeutic 
target. The induction of cell death via apoptosis using chemotherapy is not limited 
to molecular targets involved in programmed cell death pathways but can also 
be triggered by stress response to oxidative or DNA damage (Tannock and Lee, 
2001). Consequently, it is judicious to study the cell death mechanism of action 
that BNIP derivatives can induce against SW480 and SW620 CRC cell lines 
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starting with the study of apoptosis. Subsequently, underlying the cellular events 
leading to cell death is also important to design better drug delivery systems 
helping the drug to be more effective.  
 
1.4.3. Reactive oxygen species 
 
Reactive oxygen species (ROS) are radicals, ions or molecules which own an 
unpaired electron in the furthest shell of electrons such as superoxide (O2-), 
hydroxyl radical (•OH), hydrogen peroxide (H2O2) or nitric oxide (NO•) (Liou et 
al., 2010). They can be found in healthy cells as a natural by-product of the 
normal metabolism of oxygen during the mitochondrial respiration. ROS are also 
involved in several cellular signalling pathways including NFκB or MAPK (Zhang 
et al., 2016), or in immunity support with oxidative bursts during phagocytosis 
(Dahlgren and Karlsson, 1999). Although ROS are essential for the cellular 
activity, the ROS level needs to be regulated to maintain homeostasis. Low levels 
of ROS can be responsible for cardiomyopathy with the generation of reductive 
stress (Liou et al., 2010) whereas too high levels can provoke oxidative stress 
(Liemburg-Apers et al., 2015). Oxidative stress is particularly dangerous for the 
cells as it can damage cellular structures and reacts with a range of biomolecules 
such as nucleic acids or proteins. Therefore, oxidative stress can be perceived as 
a mediator of genomic instability which can lead to cell death (Cooke et al., 
2003). Consequently, there is a necessity for cells to use efficient mechanisms 
for ROS detoxification through the action of antioxidant enzymes such as 
superoxide dismutases or non-enzymatic molecules such as glutathione, 
flavonoids and vitamins A, C and E (Bardaweel et al., 2018). 
In cancer, the disruption of the ROS balance has been highlighted as an important 
cause of development and spread of cancer with most cancer cells exhibiting 
important ROS levels (Saikolappan et al., 2019). The interferences in cells’ 
signalling pathways such as NF-κB can produce an inflammatory environment 
stopping programmed cell death (Puar et al., 2018). Nevertheless, ROS can also 
be used to defeat cancer as part of the therapeutic strategy with the development 
of anti-cancer therapies focused on the generation of ROS to create oxidative 
stress (Wang and Yi, 2008). This paradoxical manipulation of ROS level relies on 
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the higher basal ROS level observed in cancer cells. Due to their abnormal 
proliferation rate, cancer cells adapt to increased ROS concentration. However, 
a chemotherapy-induced ROS generation is capable of being cytotoxic for cancer 
cells. Due to their higher ROS-survival threshold, malignant cells can then be 
selectively affected by the treatment making it more specific with less side effects 
(Kim et al., 2019). Accordingly, oxidative stress has been identified as a cancer 
therapy target and drug development has been focused on targets such as ROS 
inducing pathways or pro- and anti-oxidant regulatory proteins, notably with 
Paclitaxel (Alexandre et al., 2006) or Etoposide (Bragado et al., 2007). Hence, 
investigating the capacity of BNIPs to generate ROS levels in CRC cells could be 
an important indication of their mechanism of action which could be linked to 
DNA damage and cell death. 
 
1.4.4. DNA damage 
 
Most of the cells in the human body experience DNA lesions on multiple occasions 
every day (Lindhal and Barnes, 2000). These genetic alterations can be induced 
by chemical or physical events such as UV or chemicals exposure, thus, being 
referred to as DNA damage (Curtin, 2012). The range of DNA damage lesions 
includes single and double strand breaks but also base insertions, deletions or 
alkylation and can be responsible for disrupting DNA transcription and replication. 
In the treatment of cancer, many compounds have been identified as DNA-
damaging drugs including cisplatin, oxaliplatin doxorubicin or daunorubicin 
(Cheung-Ong et al., 2013). The first two examples are DNA crosslinkers, with a 
platinum core capable of binding guanine residues after cellular uptake forming 
DNA crosslinks. On the other hand, the last two examples, doxorubicin and 
daunorubicin, are drugs that cause single or double DNA strand breaks by 
creating a complex with topoisomerase I or II enzymes. These two enzymes are 
key participants of DNA replication and transcription for its winding, thus, making 
them effective targets.  
A complex cellular machinery is in place to repair the DNA damage caused called 
the DNA damage response which exists to maintain the genomic integrity. Minor 
changes due to base alterations can be restored by excision repair whereas more 
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serious lesions such as DNA strand breaks can be repaired by nucleotide excision 
repair (Hoeijmakers, 2009). Although different forms of DNA damage exist such 
as base alteration or single strand breaks, DNA double strand breaks (DSBs) are 
the most dangerous DNA lesions for a cell for being mutagenic and they can be 
caused by radiation of alkylating anti-cancer drugs (Rastogi et al., 2010). DNA 
repair mechanisms’ efficiencies can be limited if the level of damage is too high 
for the repair capacity of the cell. In this case, the DNA lesions can lead to 
apoptosis stopping cancer progression (Bernstein et al., 2013). On that note, 
DNA repair mechanisms have also been studied as emerging cancer therapies 
with for example the overexpression of DNA repair factors (Sato and Itamochi, 
2015). 
From the study of approved anti-cancer drugs such as doxorubicin, links between 
the generation of ROS, oxidative stress and DNA damage have been made 
(Coussens and Werb, 2002). The resulting induction of apoptosis via this 
mechanism of action has inspired the formulation of a new generation of 
chemotherapy. Based on the current knowledge of BNIPs with their high 
cytotoxicity, DNA binding properties and indication of apoptotic cell death 
induction, this project has explored the mechanism of action of these drugs in 
CRC to enhance their future therapeutic use.  
 
1.5. Aims  
 
The aims of this project were to enhance the potency of BNIP derivatives as 
chemotherapeutic drugs in the treatment of colorectal cancer by the development 
of a solid lipid nanoparticle drug delivery system and to study the mechanism of 
action of the drugs. 
In the first instance, the formulation of solid lipid nanoparticles encapsulating 
BNIPPiProp have been reported and the drug delivery system was subsequently 
characterised. Based on these results, the cytotoxicity of the BNIPs were 
evaluated in vitro in the colorectal cancer cell lines SW480 and SW620. After 
comparison with the use of the solid lipid nanoparticle (SLN) drug delivery 
system, the mode of cell death induced by BNIPs and its associated cellular 






















Encapsulating BNIP derivatives has been the chosen path to overcome the 
current limitations of this family of drugs, including their poorly solubility in 
water. Previous studies have initiated the development of a drug delivery system 
for BNIP derivatives with the encapsulation of BNIPDaoct inside CH5-
poly(allylamine) biopolymeric self-assemblies. The associated in vitro and in vivo 
studies revealed an increased aqueous solubility associated with a tumour 
reduction efficacy at a similar level to gemcitabine against pancreatic cancer 
(Hoskins et al., 2010). This study was the stepping stone into the enhancement 
of BNIPs efficacy as a cancer treatment using a nanoparticle drug delivery 
system. 
To develop a novel drug delivery carrier for BNIPs, it must be biocompatible and 
biodegradable but also non-toxic to human tissues. Solid lipid nanoparticles have 
been the carrier of choice for the BNIP derivatives as they constitute an emerging 
class of nanoparticles exhibiting several benefits compared to liposomes or 
polymeric nanoparticles, such as a greater ability to carry lipophilic drugs and an 
affordable and safe option for pre-clinical assessment (Muller et al., 2002). This 
class of particle is composed of a hydrophobic solid matrix made of solid lipids 
which can entrap efficiently hydrophobic drugs such as BNIPs. In this chapter, 
the formulation of solid lipid nanoparticles encapsulating BNIPPiProp have been 
performed and the resulting formulation has been characterised using dynamic 
light scattering for the determination of the size, PDI and zeta-potential. 
Moreover, TEM observations have been made and HPLC-UV were used to 









Tween 80 Acros Organics 
Stearic Acid Sigma Aldrich 
Trehalose Sigma Aldrich 
Span 20 Sigma Aldrich 
Acetonitrile Sigma Aldrich 
Octan sulfonic acid Sigma Aldrich 
Ethanol  Fisher Scientific 
Dimethyl sulfoxide  Fisher Scientific 
Acetic acid Fisher Scientific 
Sodium acetate Fisher Scientific 
PEG stearate Fisher Scientific 
Lecithin (72% egg) Fisher Scientific 
BNIPPiProp Synthesized in RGU 
 
Instrumentation Supplier 
Homogeniser Bennett Scientific ltd. Germany 
Freeze Dryer - Advatage 2.0 XL VirTis 
Zetasizer - nano series Malvern 





2.2.2. Manufacture of the solid lipid nanoparticles 
 
The manufacture method used to develop the BNIP drug delivery system has 
been adapted from the work of Aditya et al. (2014). The nanoparticles were 
produced using the hot homogenisation method requiring the preparation of a 
lipid phase and an aqueous phase (figure 8). The aqueous phase was prepared 
by adding 4 g of Tween 80 to 90 mL of distilled water whereas the lipid phase 
was composed of 0.5 g of Span 20, 0.5 g of egg lecithin and 4 g of stearic acid. 
 
Table 1. Summary of the composition of solid lipid nanoparticle 
formulations produced. 
 
















Ab X 4 g X 0.5 g 0.5 g 5 g X 
Ae 50 mg 4 g X 0.5 g 0.5 g 5 g X 
B X X 4 g 0.5 g 0.5 g 5 g X 
C X 4 g X X X 5 g 1 g 
D X X 4 g X X 5 g 1 g 
E 50 mg X 4 g X X 5 g 1 g 
 
  
From this original formulation, alternatives have been produced using PEG 
stearate (table 1). Both phases were then heated separately to 75°C using a hot 
plate stirrer. When both phases reached the desired temperature and the lipids 
phase was completely melted, the aqueous phase was poured into the lipid phase 
and kept on heat. Instantly, both phases were homogenised at 27,000 rpm for 
10 min. Once the mixing step was complete, the mixture was cooled at room 
temperature for 45 min and 1 g of Trehalose, used as cryoprotectant, was added 
to the cooled nanoparticle suspension. The preparation was then transferred into 
petri dishes and finally freeze-dried. 
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The previous protocol described the manufacture of the empty nanoparticles. For 
the encapsulation of BNIP derivatives, the same procedure was followed except 
for the addition of the drug to the lipid phase prior to homogenisation. The drug 
was added at a 100:1 ratio to stearic acid, thus, 50 mg of drug were added to 




Figure 8. Schematic representation of the protocol for SLN preparation 




2.2.3. Dynamic Light Scattering (DLS): particle size, polydispersity 
index and zeta potential determination   
 
All the following analysis was performed using a Zetasizer (Malvern) with a 
nanoparticle suspension at a concentration of 1 mg of freeze-dried nanoparticles 
/mL of distilled water at 25°C. The suspension was prepared by adding 10 mg of 
nanoparticles into 10 mL of distilled water. The suspension was shaken by hand 
for 20 seconds and filtered using a 0.22 µm syringe filter. For each batch, the 
analysis was performed in triplicate with the preparation of three independent 
suspensions. For the size and PDI determination, 1 mL of the filtered suspension 
was placed into a low volume plastic cuvette. For the determination of the zeta 
potential, folded capillary cells were used. These specialised containers have 
electrodes on their sides allowing an electric current to pass through the 
suspension to measure the zeta potential. Each folded capillary cell was washed 
with ethanol and water prior use and the zeta potential analysis was performed 
once for each batch of nanoparticles. Particle size and PDI analysis were 
performed in triplicate from 3 different suspensions. Zeta-potential was 
determined in triplicate from a single suspension.  
 
2.2.4. High Performance Liquid Chromatography (HPLC) to evaluate the 
drug loading 
 
Exploiting the fluorescent properties of the BNIP derivatives, Segundo et al. 
(2016) developed a validated analytical method to detect and quantify these 
compounds by using HPLC coupled with fluorometric detector. This method was 
adapted to quantify the amount of BNIP derivatives inside the nanoparticles 
allowing the use of low sample volumes with a high sample throughput. 
The HPLC system was composed of a C-18 reversed-phase monolithic column 
(Chromolith RP-18e, 100 mm × 4.6 mm i.d., Merck) coupled with a fluorometric 
detector (338 nm). The separation was performed with an injection volume of 10 
µL. An aqueous buffer (acetic acid/acetate 0.10 M, pH 4.5, 0.010 M octane 
sulfonic acid) was prepared by adding 16.64 g of sodium acetate and 3.89 g of 
1-octane sulfonic acid into 1.95 L of distilled water to be dissolved. The pH was 
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then adjusted and stabilised at 4.5 by adding acetic acid dropwise to the solution 
before the final volume of the solution were adjusted up to 2 L. The mobile phase 
used was composed of the prepared aqueous buffer and acetonitrile in a 60:40 
ratio (v/v) and was passed through the system at a flow rate of 1.5 mL/ min 
using the isocratic mode. 
To allow the quantification of BNIPPiProp using this method, calibration standards 
were prepared with the non-encapsulated drug. The standards were prepared 
using BNIPPiProp stock solution (1 mg of BNIPPiProp/ mL of DMSO) which was 
diluted in acetonitrile to obtain 6 calibration standards with a concentration 
ranging from 25 to 150 µg/ mL. 
For the nanoparticle analysis, 250 mg of freeze-dried nanoparticles was 
completely dissolved in 10 mL of acetonitrile. After optimisation, this nanoparticle 
concentration was chosen so the results were within the calibration curve. From 
the HPLC analysis, the total mass of drug detected was calculated using the 
calibration curve giving the concentration of drug. 
From the determination of the mass of drug in the analysed sample the 
percentage of drug loading was obtained as follow: 
% 𝐷𝑟𝑢𝑔 𝐿𝑜𝑎𝑑𝑖𝑛𝑔 =
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑑𝑒𝑡𝑒𝑟𝑚𝑖𝑛𝑒𝑑 (𝑚𝑔)
𝑇𝑜𝑡𝑎𝑙 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑡ℎ𝑒 𝑠𝑎𝑚𝑝𝑙𝑒 (250𝑚𝑔)
 × 100 
2.2.5. Transmission electron microscopy  
 
The transmission electron microscopy (TEM) were performed externally using the 
Electron Microscopy Research Services of the University of Newcastle. 
The negative staining procedure were first performed using solid nanoparticles 
samples at a 1 mg/mL of PBS buffer (pH 7.4) concentration. A droplet (10 µL) 
was applied to support film on 300- or 400- mesh grids held in forceps. In the 
same way, a 10 µL droplet of 2% aqueous uranyl acetate was then applied to the 
grid. After allowing the grid to dry, the grids were examined on a Hitachi HT7800 
transmission electron microscope using an Emsis Xarosa camera with Radius 




2.3. Results and Discussion 
 
2.3.1. Manufacture of BNIPPiProp-encapsulated solid lipid 
nanoparticles 
 
First, different batches of solid lipid nanoparticles have been produced with 
differences in composition as described in table 1 (section 2.2). All the batches 
were produced in triplicate and no batch-to-batch variabilities have been 
observed during the manufacturing process with no visible changes perceived. 
SLNs are composed of solid lipid, water (or organic solvent in some cases) and 
emulsifier. The lipid choice is the main factor as it influences the drug loading 
capacity as well as the drug release property and the stability of the drug in the 
nanoparticle. Here, stearic acid was chosen due to its complexity as a fatty acid 
leading to more imperfections in the lipid core structure allowing more drug to 
be encapsulated in the space created by the imperfections (Naseri et al., 2015). 
It has also been reported that this lipid in SLNs enhances the bioavailability of its 
cargo (Begum et al., 2008). 
Regarding the surfactants, they have been chosen based on their 
hydrophilic/lipophilic balance allowing the reduction of the interfacial tension 
between the lipid and the aqueous phases preventing particle agglomeration (Ma 
et al., 2009). This aggregation inhibition can also be explained by the steric 
hindrance stabilisation provided by the brush barrier formed by surfactant chains 
at the level of the nanoparticle corona (Napper, 1983; Guo and Hui, 1997). 
Surfactants consist of molecules harbouring long chains such as polyols or sugar 
derivatives allowing stearic stability (Landfester, 2001). Here, the combination 
of two non-ionic surfactants, Span 20 and Tween 80, has been used to prevent 
particle aggregation and to stabilise the nanoparticles. The phospholipid lecithin 
was also used as a co-emulsifier. Non-ionic surfactants were chosen for their 
greater hydrophobicity allowing them to solubilise poorly soluble drugs such as 
the BNIPs. Importantly, non-ionic surfactants are less toxic than cationic 
surfactants and could enhance bioavailability of the BNIPs (Wempe et al., 2009). 
The additional use of egg lecithin as a co-emulsifier was decided as this 
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amphoteric surfactant helps the preparation of a more stable colloidal system 
exhibiting both positively and negatively charged groups.  
The use of PEG stearate was also explored as a substitute for other surfactants. 
This was investigated because PEG is commonly used in the formulation of drug 
delivery systems to stabilise the nanoparticles. It has been extensively used in 
liposome formulations such as Doxil® (Barenholz, 2012). The presence of PEG in 
the formulation limits the adsorption of the immunoproteins which prevents the 
creation of a protein corona around the nanoparticles, therefore, reducing the 
digestion of nanoparticles by macrophages which cannot recognise them. This 
strategy increases the circulation time of the treatment (Müller et al., 1997). 
Additionally, Muller et al. (1997) manufactured SLNs using glyceryl 
palmitostearate which showed an impressive stability over 3 years.  
From this first manufacturing steps, all the formulations produced were 
characterized to determine their size, polydispersity index, zeta potential and 
percentage of drug loading.  
 
2.3.2. Dynamic Light Scattering (DLS): particle size, polydispersity 
index and zeta potential determination   
 
The characterisation of the manufactured nanoparticles was an essential step as 
it allowed the validation of the nanoparticle quality compared to the optimised 
original method which led to the choice of the optimal formulation to perform the 
in vitro study. The determination of the particle size, the polydispersity index 
(PDI) and the zeta potential are key to understanding the physicochemical 
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Figure 9. Physicochemical characterisation of SLNs using DLS. (A) Size 
(nm); data presented as mean ± SD, n=3 with statistical significance determined 
using a multiple comparison shown with *p<0.05, **p<0.01, ***p<0.001. and 






determined using a multiple comparison shown with *p<0.05, **p<0.01, 
***p<0.001. (C) Zeta-potential (mV), data presented as mean ± SD, n=3 with 
a p-value of <0.05 was considered statistically significant and it is represented 
by different letters corresponding to the paired batch ID showing a significant 
comparison.  
The results presented in figure 9 (A) showed that all the formulations had a 
diameter between 100 and 200 nm. Only batches Ae and C were significantly 
larger with measurements above 150 nm compared to the other batches. Ae was 
notably larger than Ab showing that the addition of the drug potentially led to a 
size increase. However, this was not observed between batch D and E.  
With the size of the gap junctions at the level of tumour cells or endothelial cells 
being 200 nm, it has been accepted that a nanoparticle delivery system should 
exhibit an average diameter of 100 nm to be able to pass through these cellular 
structures with ease (Yuan et al., 1995). Currently, clinically approved 
nanomedicine have sizes ranging from 100 to 200 nm such as DOXIL® or 
CAELYX® (Uster et al., 1998). Recently, studies showed that the miniaturisation 
of nanomedicines improved in vivo performance of the nanoparticles via a greater 
cellular uptake, and tumour inhibition when a smaller size of 50 nm or below was 
reached (Cabral et al., 2011; Tang et al., 2012). However, in the context of drug 
delivery, it is important to take other factors into consideration such as the faster 
diffusion of smaller systems out of the tumour and the renal clearance or 
lymphatic fenestration size threshold for nanoparticles smaller than 20 nm 
(Moghimi et al., 2005). Importantly for drug delivery systems, the size between 
100 and 200 nm increases the circulation time of the nanoparticles in the body 
as macrophages could capture larger particles and it can also allow enough core 
volume to encapsulate the anti-cancer agents.  
Regarding the PDI values on figure 9 (B), most batches showed PDI values below 
0.200 except for batches Ae, B and E. Significantly, batch B had a higher PDI 
(0.325) compared to all batches except batch E. The polydispersity index is 
scaled between 0 and 1. Values above 0.7 indicates a very broad size distribution 
whereas a PDI value under 0.2 indicates a monodisperse suspension (Danaei et 
al., 2018). In the case of the produced formulations, all the batches 
demonstrated a good dispersity except batch B presenting a higher value. The 
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increased polydispersity of batch B suggested that PEG stearate produced more 
polydisperse particles than with use of Tween 80 as a surfactant. However, the 
opposite effect was observed between batch C and D showing that the presence 
of PEG stearate in both phases might be responsible for the reduction of PDI 
observed in batch D. The combination of PEG stearate with Span 20 or lecithin 
might also have had undesirable interactions. The significant increase of PDI for 
batch E compared to batch D indicated that the drug encapsulation resulted in a 
more polydispersed sample.  
The zeta-potential results in figure 9 (C) showed negative values for all the 
batches. Batches Ab and E showed the highest potential with values above -20 
mV. All three batches Ae, C and D showed similar values between -20 and -25 
mV which was significantly lower than Ab and E (p<0.001). Finally, batch B 
presented the lowest zeta-potential approaching -40 mV. Zeta-potential is an 
important characterisation method as it indicates the strength of the repulsive 
force between the particles in suspension (Kathe et al., 2014). Here, all the 
batches exhibited negatives values below -10 mV which showed a good stability 
of the colloidal system. Based on their zeta-potential, the batches can be 
separated into three groups Ab, E (0 to -20 mV) > Ae, C, D (-20 to -30) > B (<-
30). Interestingly, batch B with the higher PDI exhibited the lowest zeta 
potential. Due to the greater repulsion, it could be expected that the PDI would 
be smaller, yet contrasting results were obtained. Moreover, the use of PEG 
stearate could have reduced the surface charge by acting as a shield for the 
nanoparticle corona, but this which was not observed either. Additionally, PEG 
stearate in the water phase seemed to induce a less monodisperse suspension 
with a lowest zeta-potential.  
 
2.3.3. Determination of the percentage of drug loading via HPLC 
The chromatograph in figure 10 showed a unique peak allowing quantification of 
BNIPPiProp. Using BNIPPiProp standards of known concentrations, the area under 
the curve obtained with the samples allowed to determine the amount of 
BNIPPiProp present in the samples (figure 11). The standard curve presented a 























y = 84743x - 61980
R² = 0.997
 
Figure 11. BNIPPiProp standard curve. Area under the curve (A.U.) in 
function of the concentration of BNIPPiProp [0-150 µg/mL]. Data presented as 
mean (±SD), n=3. 
The calculations, presented below, were used to determine the mass of 
BNIPPiProp in the nanoparticles and the associated percentage of drug loading. 
Figure 10. Example of BNIPPiProp-detection chromatogram. 
(obtained using the adapted method from Segundo et al. (2016) for the 
analysis of batch Ae) 
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All of the HPLC tests were carried out in triplicate and the combined results of 
the different series of batches are shown in the table 2 below. 
To determine the drug concentration within the analysed sample, the calibration 
standard equation was used: 𝑦 = 84743𝑥 − 61980  to perform the following 
calculations: 
Concentration of BNIPPiProp in µg/mL =  
𝐴𝑟𝑒𝑎 (𝐴. 𝑈. ) + 61980
84743
 
Concentration of BNIPPiProp in µg/mL =
13854599 + 61980
84743
= 164.22 µg/mL  
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑑𝑟𝑢𝑔 = 𝐷𝑒𝑡𝑒𝑟𝑚𝑖𝑛𝑒𝑑 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑠𝑎𝑚𝑝𝑙𝑒 × 𝑠𝑎𝑚𝑝𝑙𝑒 𝑣𝑜𝑙𝑢𝑚𝑒 (𝑚𝐿) 
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑑𝑟𝑢𝑔 = 164.22 × 10 =  1642.21 µ𝑔 
Once the total mass of drug was determined, the percentage of drug loading can 
be calculated as follow: 
% 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 =  
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑑𝑒𝑡𝑒𝑟𝑚𝑖𝑛𝑒𝑑
𝑇𝑜𝑡𝑎𝑙 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑡ℎ𝑒 𝑏𝑎𝑡𝑐ℎ (200 𝑚𝑔)
× 100 
% 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 =
1642.21 × 0.001
250
 × 100 = 0.66 % 
The results obtained for the batches encapsulating BNIPPiProp can be found in 
the table 2 below.  
 
Table 2. Determination of BNIPPiProp percentage of drug loading using 
HPLC-UVD. Results were calculated from the average of 3 analysis. 
Batch Area BNIPPiProp (µg/mL) % of loading 
Ae 13,854,598 164.2 0.66 
E 5,975,546 71.2 0.28 
 
Using the equation of the standard curve, the percentages of drug loading have 
been determined for the two batches encapsulating BNIPPiProp with 0.66% 
obtained for batch Ae and 0.28% obtained for batch E. There is a 2-fold increase 
in the drug loading capacity of batch Ae compared to batch E. For solid lipid 
nanoparticles, the drug loading capacity is based on the core structure of the 
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nanoparticle. With the choice of a single lipid, a more homogenous structure at 
the particle core could be observed with fewer imperfections (Mukherjee et al., 
2009). Therefore, in this homogenous matrix model, the drug can be found in 
the state of amorphous clusters (Mishra et al., 2018). This could explain the low 
percentage of drug loading obtained as a large quantity of BNIPPiProp could not 
solubilise in the lipid melt. Using an increased amount of drug (superior to the 
current 50 mg) would increase the drug:lipid ratio and potentially increase the 
drug loading.   
This observation showed that the use of a combination of lipids instead of a 
singular molecular species could yield more imperfections at the core of the 
nanoparticle. Here, the formulation with multiple lipids used only stearate lipids 
which might have led to the production of a more compact and crystalline core 
resulting in a lower drug loading.  
A first study from Fang et al. (2012) used PEG stearate onto solid lipid 
nanoparticles to encapsulate a novel chemotherapeutic agent PK-L4. The study 
showed a 99% encapsulation efficiency for their compound, and the presence of 
PEG stearate or stearic acid did not impact the loading of the drug but PEGylated 
SLNs were found to be more stable over a month (Fang et al., 2012). 
Stearic acid-based SLNs have previously been formulated for the delivery of 
Paclitaxel reporting a drug loading of 3.85%. This study evaluated different core 
lipids, thus, stearic acid demonstrated the best properties (Yuan et al., 2008). 
Drug loading values below 5% are common due to the structure of SLNs. Having 
a low percentage of drug loading, it is then necessary to use a greater mass of 
nanoparticles to reach the quantity of drug required for the treatment. 
The change in the ratio of drug/lipid could be explored to determine whether 
more drug could be loaded if the starting quantity of drug was higher. This 
difference of loading can be explained by the presence of PEG stearate instead 
of stearic acid. The drug concentration which was used did not show a disruption 




2.3.4. TEM observations 
 
TEM observations of all of the batches were obtained with the help of the 
Electron Microscopy Research Services of the University of Newcastle. 
 
 
Figure 12. TEM observations of all SLNs batches. Each batch was imaged 
using negative staining and two images (50,000 x and 100,000 x) were obtained 
for each sample.  
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The TEM pictures (figure 12) enabled the visualisation of the spherical shapes of 
SLNs for all the batches. It is important to notice that the particle sizes obtained 
using TEM are smaller than the DLS measurements. This can be explained by the 
differences of methodology as DLS measures hydrodynamic sizes, whereas the 
TEM requires the samples to be dried on the grid leading to a reduction in the 
particle size due to the loss of water content. This phenomenon can also be 
observed with the use of EvoView™ systems which determine the size of 
exosomes after the drying of the natural nanoparticles on a chip. To obtain more 
robust data, nanoparticle tracking analysis could be performed to have a third 
method of validating the size of the different batches (Mourdikoudis et al., 2018). 
Between batches Ab and Ae, respectively blank and loaded SLNs, no changes of 
shape were observed. The particles observed for batch C appeared to have more 
regular edges than the other batches such as A. Interestingly, particles of batch 
D exhibited a halo representing twice the size of the core of the particle. This 
halo could be due to the presence of PEG stearate and visible only in D due to 
the quality of the samples exhibiting the lowest PDI value. Finally, batch E 
showed a similar appearance to batch A, indicating that the presence of 
BNIPPiProp appeared to have no consequence on the structures observed by 
TEM.  
Staining contrast differences observed for batches C-E compared to batches A 
and B showed that structural differences might exist between these batches with 
the deep and regular staining for batches A and B potentially indicating the 
presence of SLN due to their dense solid core. For batches C-E, the presence of 
PEG stearate could be producing a bilayer structure around the nanoparticle, a 
structure that can be found similarly in liposomes or extracellular vesicles. The 








2.4. Conclusion  
 
In this chapter, the successful formulation of solid lipid nanoparticles 
encapsulating BNIPPiProp has been reported. Although all the formulations 
presented viable physicochemical properties to continue into the in vitro study, 
batch Ae were chosen as it presented the highest percentage of BNIPPiProp 
loading with 0.66%. Moreover, the physicochemical properties were consistent 
between the empty and loaded SLNs. Further optimization of this formulation 















In vitro study: exploring the cytotoxicity and the 






To study the potential of BNIPPiProp, BNIPDaCHM and BNIPPiEth as anti-cancer 
drugs for the treatment of colorectal cancer, the cell lines SW480 and SW620 
were selected as previously discussed in section 1.4.1.  
From the results obtained in the formulation section where a solid lipid drug 
delivery system was made for BNIPs, batch Ae was chosen for further studies 
against colon cancer cell lines SW480 and SW620. Any improvement in the anti-
cancer activity of BNIP as a result of applying SLN delivery system will be 
analysed and discussed. Cytotoxicity studies using the native BNIPs drugs and 
the encapsulated BNIPPiProp were performed using the MTT assay. From those 
results, the possible mechanism of action of the BNIPs derivatives was studied in 
those colorectal cancer cell lines after evaluating the ROS levels, the DNA damage 









Dimethyl Sulfoxide Aldrich, UK 
Reactive Oxygen Species (ROS) Detection 
Assay Kit 
Biovision, USA 
Caspase-3 Colorimetric Assay Kit BioVision, USA 
CaspGLOW™ Fluorescein Active 
Caspase-3/7 Staining Kit 
Biovision, USA 
Bio-Rad Protein Assay Kit  Bio-Rad, UK 
Leibovitz's media Gibco, UK 
Penicillin/Streptomycin Invitrogen, UK 
Hydrogen Peroxide Fisherbrand, UK 
Sodium Hydroxide   Fisherbrand, UK 
Tris Base  Fisherbrand, UK 
Sodium Chloride Fisherbrand, UK 
AnnexinV/ PI kit Nexcelom Bioscience, UK 
Human Apoptosis Array kit  R&D systems, USA 
Proteome Profiler Array  R&D systems, USA 
Ethylenediaminetetraacetic acid  Sigma-Aldrich, UK  
Phosphate buffered saline  Sigma-Aldrich, UK 
Methylthiazolyldiphenyl-tetrazolium bromide Sigma-Aldrich, UK  
Agarose (1% w/v)  Sigma-Aldrich, UK  
Low Melting Point Agarose Sigma-Aldrich, UK  
Agarose Sigma-Aldrich, UK  
Triton X-100  Sigma-Aldrich, UK  
Trypsin-EDTA Sigma-Aldrich, UK 









96-well plate reader Synergy/HT, BIOTEK, USA 
ALC Multispeed Refrigerated Centrifuge Thomson Scientific, UK  
Electrophoresis Tank Bio-Rad, UK 
CL-XPosure X-ray film Thermoscientific, UK 
BIO-1D™ imaging software  PeqLab, UK 
FUSION-FX7 Vilber, Germany  
HERACell incubator Heraeus, Germany  
Haemocytometer Neubauer, Germany 
Leica DMIL light microscope Leica Microsystems, UK  
HERASafe Class II Safety Cabinet 
Thermo Electron Corporation, 
Germany 
Cellometer  Nexcelom Bioscience, UK 





3.3.1. Cell maintenance and culture 
 
Both SW620 and SW480 (from American Type Culture Collection) cell lines were 
grown in an incubator at 37°C with 5% CO2 in a humidified atmosphere. The cell 
culture medium was Leibovitz's L-15 which was supplemented with 10% Foetal 
bovine serum (FBS) and 1% Penicillin/ Streptomycin (named 10% Leibovitz’s 
thereafter). The media was stored at 4°C and warmed up to 37°C prior each use.  
Originally stored in liquid nitrogen, cells were recovered by slowly defrosting the 
vials. Fifteen millilitres of 10% Leibovitz’s medium was added to a 75 cm² flask 
in which 1 mL of cell suspension was transferred. The cells were incubated at 
37°C under 5% CO2 for 24 hours. The next day, the medium was discarded, the 
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cells washed with PBS to remove any dead cells and traces of DMSO 
(=cryoprotectant) before the addition of 15 mL 10% Leibovitz’s.  
The cells grew in optimal conditions when the medium was changed every three 
days. When the cells reached around 70-80% confluence, the medium was 
removed, and the cells were washed twice with 5 mL PBS. One mL Trypsin/EDTA 
was then added to the cells for 5 mins at 37°C. Once the cells detached, 5 mL 
10% Leibovitz’s was added to inhibit the effects of the trypsin. The cell 
suspension was then centrifuged for 5 mins at 500 xg (ALC centrifuge). The 
supernatant was discarded, and the cell pellet resuspended in 10 mL 10% 
Leibovitz’s.  
The cells were enumerated using a haemocytometer. Fifteen µL of cell suspension 
was inserted inside one of the counting chambers. Cells were counted using a 
light microscope. The cells in the sections A, B, C and D (figure 13) of the 
chamber were then counted. 
 
Figure 13. Haemocytometer gridlines (adapted from Abcam.com). 
Then, the cell concentration was determined by the following equation: 
[(A+B+C+D)]/4] × 104 ×Dilution Factor = number of cells/mL   
The required cell concentrations were then calculated and cells were seeded 









3.3.2. In vitro treatment with BNIP derivatives 
 
The BNIP derivatives were synthesised by Prof Kong at the Robert Gordon 
University, Aberdeen, in the School of Pharmacy and Life Sciences. For each BNIP 
derivative, a 10 mM stock solution were prepared in DMSO/ water (50/50; v/v) 
and stored at 4°C until use.  
Prior to cell treatment, the stock solutions were warmed up using a heat gun to 
ensure complete dissolution of the drugs in DMSO/water. They were then diluted 
in 10% Leibovitz’s.  
 
3.3.3. MTT assay  
 
To assess the cytotoxicity of the BNIPs on SW480 and SW620 cells, MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays were performed. 
The cells were seeded at 2.5x104 cells/well/100 µL in 96-well plates. After 24 
hours, BNIPPiProp, BNIPDaCHM and BNIPPiEth treatment solutions were 
prepared at concentrations ranging from 0 to 5 µM and they were added to the 
cells for 24 hours.  
Once the BNIP treatment was completed, the solution was removed and 100 µL 
MTT solution (1 mg/ml MTT in 10% Leibovitz’s, prepared in the dark and filtered 
with a 0.2 µM filter) was added to each well. The plate was then incubated for a 
further 3 hours, in the dark at 37 °C. The wells were then emptied and 200 µL 
DMSO was added to dissolve the formazan crystals formed for 15 mins under 
agitation. The absorbance was then read at 560 nm on the plate reader. The data 
was acquired with the Gen5 software and IC50 determined. 
 
3.3.4. Annexin V/ PI detection using image cytometry 
 
To understand the mode of cell death in SW480 and SW620 cells triggered by 
BNIPs, image cytometry was used. Annexin V/PI detection was performed to 
determine if BNIPs were triggering cell death via apoptosis. In 6-well plates, 
742,500 cells were seeded in each well and were incubated for 2 hours at 37°C. 
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The existing medium was then removed, and the cells were treated with the 
BNIPPiProp at its IC50 value, for 2 hrs. In each assay, a negative control 
(untreated cells) was included. After incubation, the cells were collected as 
previously described and the cell pellet was resuspended in 0.3 mL PBS. The cell 
concentration was determined using the counting mode of the image cytometer 
and the sample concentrations were adjusted to 2 x106 - 3 x106 cells/mL. Fifty 
microliters of the cell suspension were added, centrifuged at 500 xg for 5 mins 
and the supernatant discarded. The cell pellet was resuspended in 40 μL Annexin 
V binding buffer and 5 μL Annexin V-FITC and 5 μL PI solutions were then added 
(respectively Nexcelom Part# CS1-0114 and 0116). The samples were then 
incubated for 15 mins in the dark at room temperature. Two hundred and fifty 
microliters of PBS were then added, and the cells were centrifuged as before. The 
supernatant was discarded, and the cells resuspended in 40 μL Annexin V Binding 
Buffer. Using a microscope slide from the kit, 20 μL of cell suspension was added 
to each chamber and analysed using the Annexin V/PI detection mode of the 
Nexcelom Vision software. The data was analysed using the FCS Express 4 
software.  
 
3.3.5. COMET assay 
  
To study the effects of BNIPs on DNA damage, SW480 and SW620 cells were 
seeded on 6-well plates at 742,500 cells/well with 3 mL 10% Leibovitz’s and 
incubated for 24 hours. The BNIP treatment at its IC25 value was then prepared 
and added to the wells, then the plates were placed in the incubator for 24 hours. 
Once the treatment was completed, each well was emptied and washed twice 
with PBS. Five hundred microliters of Trypsin/EDTA were then added and the 
cells were collected in 1.5 mL centrifuge tubes. The cell suspensions were 
centrifuged at 400 xg for 5 mins at 4°C. During the centrifugation, 85 µL agarose 
was poured on frosted microscopy slides covered with 18x18 mm cover slips. The 
slides were placed for 10 mins at 4°C to solidify. After centrifugation, the 
supernatant was discarded, and the cell pellet was resuspended quickly into 85 
µL LMP agarose solution and the mix was poured onto the pre-coated microscope 
slides (existing cover slip removed prior to addition of the second layer). The 
52 
 
final two-layer gel was covered with a 18x18 mm cover slip and the slides were 
kept at 4°C for 10 mins.  
The slides were then placed into a black staining jar containing 200 mL lysis 
buffer (2.5 M NaCl, 0.1 M EDTA, 10 mM Tris Base, 1% (v/v) Triton-X-100, NaOH 
pH=10) for 60 mins at 4°C. An electrophoresis tank was set up at 4°C (cold 
room) and was filled with electrophoresis buffer (0.3 M NaOH, 1 mM EDTA, pH 
13). The slides were placed horizontally in the electrophoresis tank and left to 
equilibrate for 40 mins. The electrophoresis was subsequently carried out at 25 
V (999 mA) for 30 mins at 4°C. The slides were then washed 3 times for 5 mins 
with cold neutralising buffer (0.4M Tris, pH 7.5) and stained with 20 µL 1 µg/mL 
DAPI and covered with a 22x22 mm cover slip. The comets were analysed with 
a fluorescent microscope (Leica DMRB fluorescence microscope with D filter (ex: 
355 – 425 nm – em: 470 nm). Comets were discriminated into 5 different classes, 
each representing a different level of DNA damage. One hundred comets were 
counted per gel giving a score from 0 (no damage) to 400 (high damage) 
(arbitrary unit). 
 
3.3.6. Reactive oxygen species level detection 
 
ROS level was detected using the ROS detection kit from BioVision. ROS detection 
was performed to evaluate the level of ROS present after BNIP treatment as an 
increased level could explain the triggered apoptosis and DNA damage revealing 
another aspect of BNIPs’ mechanism of action.  
For each cell line, 2.5 x 104 cells (200 µL) were seeded per well in a 96-well plate 
and were incubated for 24 hrs. The medium was removed after 24 hrs and 100 
µL ROS assay buffer was added to wash the cells. Then, 100 µL of the ROS 
labelling solution (H2DCFDA) was added and the plate was incubated for 45 mins 
at 37°C in the dark. After incubation, the dye solution was removed, and the cells 
were washed as before. The BNIP treatment (BNIPDaCHM, BNIPPiProp and 
BNIPPiEth at their IC25 and IC50 values) solutions were then added to the wells 
(100 µL) for 24 hrs. At the end of the treatment, the fluorescence was measured 
at Ex/Em = 495/529 nm in end point mode using a plate reader and the data 
was acquired with the Gen5 software.  
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3.3.7. Protein assay 
 
In this project, the protein assay was used to quantify the total protein content 
in the cell lysate for the caspase 3 assay and the human protein array (described 
in sections 3.10 and 3.11). A concentration range (0 to 1.25 mg/mL) of Bovine 
Serum Albumin (BSA) standard solution, containing 1% Triton-X, was prepared. 
The protein lysates were diluted 1:2 and 5 µL of sample (in duplicate) or standard 
(4 replicates) were added to the wells of a 96-well plate. From the BioRad Protein 
Assay Kit, 25 µL solution A was added followed by 200 µL of solution B according 
to the manufacturer’s instructions. The plate was incubated at room temperature 
for 15 mins and then read at 650 nm on the plate reader using the Gen5 software 
to acquire the data. The total protein concentration (in mg/mL) was determined 
using the equation of the BSA standard curve.  
 
3.3.8. Caspase-3 colorimetric assay 
 
Caspase-3 is a well-known marker of apoptosis, so its activity was assessed to 
further understand the mechanism of cell death triggered by BNIPs in both cell 
lines (Elmore, 2007). This assay was performed using the BioVision Caspase-
3/CPP32 Colorimetric Assay Kit. Cells were seeded at 1.5 x 106/T25 flask/ 5 mL 
10% Leibovitz’s in duplicate and BNIPDaCHM, BNIPPiProp and BNIPPiEth were 
used at their respective IC25 concentration. After 24 hours, the medium was 
removed, and the cells collected as before. The cell pellet was resuspended with 
50 µL cold cell lysis buffer and the cell suspension was incubated on ice for 10 
mins. The suspension was centrifuged for 1 min at 10,000 xg. The supernatant 
containing the cytosolic extract was transferred to a new tube and stored at -
20°C until further use.  
The protein concentrations were determined as described in section 3.3.7 and 
each sample was then prepared to have 150 µg total protein in a 50 µL final 
volume with cell lysis buffer. The samples were added to a 96-well plate and 50 
µL 2X reaction buffer (containing 10mM DTT) and 5 µL of the 4mM DEVD-pna 
substrate (200 µM final concentration) were added. The plate was incubated at 
37 °C for 2 hrs before being read at 405 nm on the plate reader. The data was 
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acquired as stated before and the results for each sample were standardised to 
the control (untreated) for each experiment. 
 
3.3.9. Human apoptosis protein array 
 
The Human Apoptosis Array Kit was used to determine the expression profile of 
apoptosis related proteins in SW620 and SW480 cells after treatment for 24 hrs 
with IC25 BNIPs. The array allows for the detection of 35 apoptosis-related 
proteins, each spotted in duplicate on the membrane, 
After treatment, following the manufacturer’s instructions 
(www.rndsystems.com), the medium was removed and 2 mL lysis buffer was 
added to the cells and incubated for 30 mins. The solution was collected and 
centrifuged at 14,000 xg for 5 minutes. The protein concentration was 
determined as described in section 3.3.7. For each array membrane, 200 μg 
protein was used and was made up to 250 μL final volume with PBS. The 
membranes were blocked with the Array Buffer for an hour. Fifteen µL of the 
detection antibody cocktail were added to the protein samples and the mixture 
was added to the membrane for 1 hr at 4°C with continuous shaking. The protein 
solution was discarded and each membrane was washed 3 times (10-minute 
wash) before being incubated with 2 mL Streptavidin-HRP solution for 30 mins. 
The solution was discarded and the membrane washed as before. 
Chemiluminescence detection reagents (1/1; v/v) were then added on top of the 
membrane and incubated for 1 minute in the dark. In the dark room, the 
membrane was then exposed to an X-Ray film for 10 minutes. The film was 
developed by soaking it in developer for 1 min, then washed briefly in tap water 
and finally fixed in fixing solution for 1 min. The film was rinsed and left to dry 
prior analysis. 
A picture of the film was taken on the FUSION FX7 imaging system and the pixel 
density of each spot was then analysed using the FUSION FX7 imaging software. 
Quality control spots are present on each membrane with positive spots needing 
to be pixel dense and negative spots with no colour change. Monitored on each 
membrane, these spots validate the good execution of the protocol. The average 
signal i.e. the pixel density was determined for each spot and an average of each 
55 
 
duplicate was calculated. The data was then analysed by removing the average 
pixel density of the negative control (PBS) to determine the relative changes in 
the expression of the protein of interests. For each set of four membranes, the 
treatments were the following: BNIPPiProp (24 hrs IC25), BNIPPiEth (24 hrs IC25), 
BNIPDaCHM (24 hrs IC25) and control without BNIP treatment. The data was 
analysed as a ratio treatment/control to evaluate the relative protein expression 
levels.  
 
3.3.10. Statistical analysis 
 
Unless otherwise stated, each experiment was performed at least 3 times 
independently. The data was expressed in relation to the relevant controls and 
presented accordingly. Statistical analysis was performed using GraphPad Prism 
8.0 software (GraphPad Software, San Diego, CA, USA).  
Statistical significance was assessed with: 
-  the Student’s t-test with *p<0.05, **p<0.01, ***p<0.001. 





3.4. Results and discussion 
 
3.4.1. The effects of BNIPs and SLN-loaded BNIPPiProp on cellular 
cytotoxicity on colorectal cancer cells 
 
The use of formazan dyes is one of the most common methods to determine 
cytotoxicity. The formazan dyes are chromogenic compounds produced by 
tetrazolium salts’ reduction (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) or 2,3-bis-(2-methoxy-4-nitro-5-
sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT)) by dehydrogenases (lactate 
dehydrogenase) and reductases, and they are released during cell death (Fathin 
et al., 2017). The principle of these assays relies on the fact that dying cells often 
present serious structural damages allowing the release of intracellular content 
and the admission of fluorescent dyes inside the cells. Importantly, the MTT assay 
relies on the enzymatic reduction of the MTT compound to the purple crystal 
formazan which is obtained once MTT has been catalysed by mitochondrial 
succinate dehydrogenase.  
In this study, the cytotoxicity of both the naked BNIPs and the encapsulated 
drugs in the lipid nanoparticles has been assessed against SW620 and SW480 




3.4.1.1. The effects of BNIPs on cell cytotoxicity on colorectal cancer 
cells 
 
The results presented in figure 14 show the effect of BNIPDaCHM, BNIPPiProp 
and BNIPPiEth on colorectal cancer cells after a 24-hour treatment. The 
percentage of cell viability decreased with the increase of BNIP concentrations 
up to 5 µM. This cytotoxic effect has been observed against both cell lines using 
these 3 compounds.  
From the MTT assay results, the IC50, i.e. the concentration for which 50% of 
cells are dead compared to the solvent control cells, was determined and 
summarised in table 3; IC25 values were also determined. The half maximal 
inhibitory concentration was very useful as it allows the direct comparison of the 

















































Figure 14. MTT Assay: the effects of BNIPDaCHM, BNIPPiProp and 
BNIPPiEth against SW620 (A) and SW480 (B) cells after a 24 hr-
treatment. The data are expressed as percentage of the solvent control 





Table 3. IC50 and IC25 determined from the MTT assay after the 24-hr 
treatment with BNIPPiProp, BNIPDaCHM and BNIPPiEth against SW620 
and SW480 cell lines.  
 
 
In SW480 cells, the three drugs had similar IC50 values between 2.2 and 2.6 µM. 
However, for SW620 cells, BNIPDaCHM and BNIPPiEth were more toxic with 
respective IC50 values of 1.3 and 1.6 µM. Moreover, in both cell lines, the 3 BNIP 
derivatives have exhibited a similar cytotoxic profile showing that the metastatic 
characteristics of SW620 are not leading to a resistance to BNIP cytotoxic effects, 
as no significant difference has been observed between the two cell lines. 
Thus, three drug candidates were tested for the first time against SW480 and 
SW620 cell lines, however, BNIPs cytotoxic effects have already been studied 
against several other cell lines. The three drugs presented IC50 values ranging 
from 1.8 to 3.3 µM against MDA-MB-231 and from 0.3 to 0.7 µM against SKBR-
3 making them strong candidates as anti-cancer drugs by exhibiting such potent 
cytotoxic effects (Kopsida et al, 2018). Kopsida et al. (2018) also showed that 
BNIPPiEth was the most cytotoxic drug in both MDA-MB-231 (1.8 µM) and SKBR-
3 (0.3 µM) breast cancer cell lines compared to BNIPDaCHM and BNIPPiProp. 
These cytotoxicity studies on different in vitro models have shown that this 
generation of BNIPs has consistently high cytotoxicity potency across several 
cancer cell lines with IC50 values ranging from 0.3 to 3 µM. 
In comparison to other anti-cancer drugs, all three BNIPs have presented much 
lower IC50 values. Other compounds that have been tested on SW480 and SW620 
cell lines have shown to be more effective in SW480 than in SW620 cells. SW620 
cells represent a metastatic cell line which is known to show chemoresistance 
against drugs such as 5-fluouracil used widely in colorectal cancer treatment 
(Tentes et al., 2010). For examples, gold standard agents against colorectal 















SW480 2.2 2.6 2.6 1 1.7 0.8 
SW620 1.3 2.3 1.6 0.75 1.6 2.1 
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fluorouracil (541.20; 497.80), oxaliplatin (43.31; 104.70), geldanamycin (45.59; 
59.00) or novobiocin (139.20; 155.10) (Slater et al, 2018). This study has 
established that chemosensitivity varied upon the cell line and the drug tested. 
Presenting lower IC50 values with an average of 2 µM, the BNIPs represent strong 
candidates for the treatment of CRC.  
Having established the robust cytotoxicity provoked by the use of BNIPs against 
both SW480 and SW620, these results also provide essential data for the 
comparison of the efficacy of the encapsulated-drug compared to the free-drug 
treatment in vitro. 
 
3.4.1.2 The effects of SLN-encapsulated BNIPPiProp on cell cytotoxicity 
on colorectal cancer cells 
 
The results reported in figure 15 (A), present the effects of SLN-encapsulated 
BNIPPiProp on the colorectal cells’ cytotoxicity levels compared to the drug 
delivery system (SLN) alone. For each treatment at a specific concentration, the 
level of nanoparticles required to reach the targeted drug concentration has been 
calculated based on the percentage of drug loading (Chapter 2). For each SLN 















































Figure 15. MTT Assay: evaluation of the percentage of cell viability of 
BNIPPiProp-encapsulated in solid lipid nanoparticles against SW620 
(A) and SW480 (B) after a 24 hr-treatment. The data are expressed as 
percentage of the solvent control (DMSO/H2O) and are presented as mean ± 
SEM of 3 in dependent experiments (n=3). The concentrations are the 
theoretical drug concentration calculated based on the percentage of drug 
loading in SLNs.  
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Table 4. IC50 values determined with the MTT assay from the 24-hr 
treatment using BNIPPiProp encapsulated in SLN against SW620 and 
SW480 cell lines with the empty SLN used as a control.  
 
IC50 -Concentration (µM) SLN Control BNIPPiProp-SLN 
SW480 6 4.5 
SW620 5 2 
 
The results presented in figure 15 (B) show that the empty nanoparticles had a 
high level of toxicity with IC50 values of 6 and 5 µM against SW480 and SW620 
respectively after 24 hrs. However, with nanoparticles encapsulating BNIPPiProp, 
the IC50 obtained was lower against each cell line with a value of 1.5 µM against 
SW480 and 3 µM against SW620 (table 4). Since high toxicity levels from the 
drug delivery system itself were observed in both cell lines, the cytotoxicity 
results from the encapsulated BNIP were not comparable as toxicity might have 
come from either the drug or/and the delivery system itself.  
This formulation without drug loaded was tested in a previous project (personal 
communication) where the control SLNs did not show any toxicity against MDA-
MB-231 breast cancer cells. The solid lipid nanoparticles tested against colorectal 
cancer cells could present toxicity due to the high nanoparticle density in the well 
that could have led to a poor access to essential nutrients for the cells. This data, 
showing different cytotoxicity profiles using the nanocarrier alone, suggests that 
the decrease of cell viability was cell-specific as it was observed for colorectal 
cancer cells only in this case. 
Solid lipid nanoparticles are composed of lipids and surfactants and it has been 
shown that the nature of lipids has no effect on viability as they are safe 
physiological compounds (Wissing et al., 2004). However, surfactants can cause 
cytotoxicity (Müller et al., 1997). The non-anionic surfactant Tween 80 used in 
this formulation is known to be the least toxic surfactant among the most widely 
used and all the selected components were FDA approved (Prieto and Calvo, 
2013). Further investigations are required to understand the origin of the 
cytotoxicity of the nanoparticles. The more detailed nanotoxicology profile should 
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include the cellular uptake of the formulations and the study of the cell processing 
routes employed (Severino et al., 2012). 
When BNIPPiProp was encapsulated in solid lipid nanoparticles, the IC50 values 
were 6 and 5 µM for SW480 and SW620 cells respectively. Therefore, achieving 
a high drug encapsulation would reduce the required number of nanoparticles 
per treatment and consequently, working with significantly decreased 
concentrations of particles to reach an IC50 could solve the toxicity issue.  
Here, the potential of BNIPDaCHM, BNIPPiEth and BNIPPiProp as potent anti-
cancer drugs against SW480 and SW620 colorectal cancer cells has been 
established in relation to their cytotoxicity. After 24 hours treatment, all three 
drugs have demonstrated strong cytotoxicity with IC50 values ranging from 1.3 
to 2.6 µM. However, with the use of SLNs encapsulating BNIPPiProp, no 
conclusion on its relative cytotoxicity can be established due to the unforeseen 
cytotoxicity of the control SLN. Optimisation of the formulation will be required 
to obtain a non-toxic drug delivery system. 
Due to this difficulty, the mechanism of action of the BNIP derivatives was then 
studied in order to have a better understanding of the biological events occurring 
after drug treatment. Obtaining this knowledge is key in the design of more 
efficient nanodrug delivery systems tailored to the delivery of BNIP derivatives 




3.4.2. Investigating the mechanism of cell death with image cytometry 
 
Chemotherapy is by definition the use of chemicals to destroy cancer cells. BNIPs 
are part of this type of compounds as previously demonstrated with the 
cytotoxicity study. However, there are different classes of chemotherapy agents 
which can be separated upon their mechanism of action such as alkylating 
agents, anti-metabolites or enzyme inhibitors (Huang et al., 2017). For the last 
50 years, a main target for anti-cancer treatment has been nucleic acids as the 
modification of the DNA mechanisms (replication, repair or transcription) can 
lead to programmed cell death (Brana et al., 2001). Apoptosis is recognised as 
the principle chemotherapy-induced mode of cell death. However, accumulating 
evidence proposes the induction of other modes of cell death such as autophagy 
(Brown et al., 2005). BNIP derivatives have demonstrated the ability to bind to 
DNA via bis-intercalation using their naphthalimido group (Barron et al., 2010) 
and to cause DNA damage in other cell lines (MDA-MB-231 and MCF-10A cells). 
Therefore, this project has chosen the assessment of apoptotic cell death as a 
first step to better comprehend the mechanism of action of BNIP derivatives 
against CRC. 
To investigate cell death by the activation of apoptotic pathway, an image 
cytometry method was chosen to perform a pilot study. Image cytometry, also 
called slide-based cytometry, is a microscopy-based technique which uses 3 
imaging channels to quantify fluorescence intensities. Coupled to a cell counting 
software, the cell sample is counted, and a data set is generated similar to a flow 
cytometry plot where cells populations can be distinguished depending on their 
fluorescence signal. Here the Cellometer from Nexcelom® was used to study the 
mode of cell death in SW620 after treatment with BNIP derivatives. This pilot 
study aims to develop the use of image cytometry in the detection of apoptosis, 
to obtain a rapid method to screen drug candidates in relation to cell death and 




3.4.2.1. Optimisation of the image cytometer for the in vitro model 
 
Image cytometry is the oldest form of  cytometry using optical microscopy to 
image a population of cells entrapped on a slide (Shapiro, 2004). The progress 
of this technology has used fluorescent filters thus allowing the application of 
fluorescent dyes to the study of biological mechanisms. The use of image 
cytometry was preferred compared to flow cytometry as this technique is less 
time consuming with a slide analysis performed in seconds on the benchtop. It 
also provided fluorescent images of the results allowing the visualisation of the 
positive/ negative cells making the method ideal for a pilot study.  
To optimise the system for SW480 and SW620 cells, the morphology of the cells 
was studied first with different fields to ensure that the cells were recognized as 









Figure 16. Illustration of the difference of focus obtained with the 
cellometer microscope in bright-field (10X magnification). 
 
Once the system was set up to recognise the cells’ morphology, different cell 
densities were loaded in the counting chamber to determine the optimum cell 
number to obtain the highest number of cells without saturating the counting 
software. 
 




Figure 17. Illustration of the cell counting chamber using different cell 
density (SW620) with the Cellometer microscope in bright-field mode 
(10X magnification). 
 
Based on a 60-70% on-screen confluence level recommended by the 
manufacturer, the optimum cell density for SW620 was set at 2 million cells/mL 
for all subsequent experiments (figure 17). This initial test should be performed 
for each newly used cell line at the start of every study. 
With the optimum cell concentration determined, the cell number was then 
assessed on the image cytometer and compared to the haemocytometer manual 
counting method (figure 18). The data showed no statistical difference and a very 
good reproducibility between the two cell counting methods. 
  




Figure 18. Comparison of the automatic counting (cellometer) and 
manual counting (haemocytometer) methods. The experiment has been 
performed in triplicate (n=3) from a SW620 cell suspension. Results are 
expressed as mean ± SD. 
 
The results obtained were very similar using the two methods, thus validating 
the use of the automated counting system with no additional cell counting 
adjustments for its use in section 4.2. The automation of the cell counting process 
could also be generalised to routine cell maintenance to enumerate cell 
populations reducing the time required and the potential human error (Gupta et 
al., 2019).  
Following the validation of the key system components relative to optical cell 





3.4.2.2. The effects on BNIPs on apoptosis in SW480 and SW620 cell 
lines   
 
3.4.2.2.1. Annexin V/Propidium Iodide 
 
To measure apoptosis, Annexin V (A5) and propidium iodide (PI) detection has 
been chosen as they were detectable simultaneously using the fluorescence 
filters of the cellometer. Annexin V is part of the Annexin group of proteins which 
are intracellular, and bind specifically to phosphatidylserine (PS) in the presence 
of calcium. PS is a common phospholipid found within the cellular membrane and 
exposed at the intracellular level. However, during apoptosis, PS is translocated 
and has an extracellular detectable exposure (Vermes et al., 1995).  
A5 can then be used to detect PS present on the cell surface. The use of A5 on 
its own is not sufficient as there would be no differentiation between necrotic or 
late apoptotic cells which all exhibit PS. PI is then used, as early apoptotic cells 
will exclude PI therefore being only A5 positive. SW620 cells were incubated for 
2 hrs with IC25 to IC75 BNIPPiProp concentrations to study the A5/PI detection on 




Figure 19. FCS software reports of the detection of Annexin-V and PI 
after a 2 hr-treatment with BNIPPiProp against SW620. 
 
The FCS software reports (figure 19) showed the cytometry plots with the black 
cross representing the gating. The gating was set manually using control 
experiments with no drug treatment and it was kept the same for the rest of the 
study. The software provided the results as a percentage of gated cells having 
counted the total number of cells on the slide prior fluorescent analysis. Cells 
with fluorescent intensities below the gating level for both Annexin V and PI were 
considered live cells. Cells positive to PI only were considered debris and cells 
positive to annexin V only were considered apoptotic. Finally, the cells were 
considered necrotic if positive to both fluorescent probes. This testing has allowed 
the optimisation of the fluorescence parameters on the system with exposure 





Figure 20. Annexin V/PI detection: determination of the level of early 
apoptotic cells after treatment with BNIPPiProp using different 
exposure times (A) and different concentrations after 2 hrs (B). The 
percentage of apoptotic cell death is compared to untreated cells (control). The 
experiment has been performed in duplicate for each test. 
 
The initial optimisation of the system and of the software allowed the 
development of an in vitro assay using the image cytometer. Figure 20 (A) 
showed the results of Annexin V and PI detection using BNIPPiProp at IC25 
concentration at different exposure times against SW620. Although the 30 mins 
time point showed no increase in apoptotic cells, the 2-hr time point showed the 
best result with a 3.5% increase. Using that time point, different concentrations 
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(IC25, IC50 and IC75 were then tested (figure 20 (B)). The highest increase in 
apoptotic cells was observed using IC50 with a 1% increase compared to 
untreated cells.  
Detection of early apoptosis using annexin-V relies on the flip of phosphatidyl 
serine which would mainly occur during the first 4 hrs of incubation with a 
cytotoxic agent (Zhang et al., 1997). To validate the use of this assay on the 
cellometer, the same experiment could be repeated with the use of flow 
cytometry and using the other two compounds. 
This testing has allowed the optimisation of the fluorescence parameters on the 
system with exposure settings set at 2,000 ms. This preliminary test is promising 
for the use of image cytometry to detect the effect of BNIPs on apoptosis, and 
more compounds on both cell lines should be tested. However, the use of other 
methods of apoptosis detection such as the detection of the caspase cascade 
activation, the detection of cytochrome c release or the cleavage of anti-apoptotic 
Bcl-2 proteins would be required to support this preliminary data. 
 
3.4.2.2.2. Detection of Caspase 3/7 activity 
 
As with Annexin V/PI, Caspase 3/7 activity allows the detection of apoptotic cell 
death. Annexin-V shows the translocation of phosphatidylserine to the outer 
membrane which is an event that occurs during early apoptosis. However, 
caspase activity assesses the cleavage of members of the cysteine aspartic acid-
specific protease (caspase) family which play a crucial effector role in the 
mediation of apoptosis. Caspase 3 and 7 are the activated form of procaspases 
3 and 7 which are inactive cysteine proteases. After activation during apoptosis, 
a signalling cascade cleaves the procaspases, activating them and leading to the 
irreversible programmed cell death (Martinez et al., 2010). Based on the small 
increase of apoptotic cells detected with annexin V/PI, this method was used to 
confirm the first indications previously obtained. 
The CaspGLOW™ Fluorescein Active Caspase-3 or Caspase 7 Staining Kit is a 
rapid method for the detection of Caspase 3 or 7 in living cells. The test uses 
FITC-conjugated active-caspases 3/7 ligands (DEVD-FMKs) which can penetrate 
living cells and bind to these active caspases. The FITC-binding allows the 
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detection of the complex, formed with fluorescence detection using image 
cytometry. The resulting data is plotted as a histogram displaying the percentage 




Figure 21. Caspase 3/7 detection: percentage of apoptotic cells after 
24 hr-treatment with BNIPPiProp, BNIPDaCHM and BNIPPiEth against 
SW480 and SW620 (excluding BNIPPiEth against SW480). The 
percentage of apoptotic cells is normalized to the untreated cells control; n=2. 
 
In figure 21, BNIPs modified the level of expression of caspase 3/7 after 24 hr 
incubation at IC50 concentrations. Compared to untreated cells, an increase in 
the percentage of apoptotic cells was observed for the 3 drugs in this study 
ranging from a 11 to 46% increase. BNIPPiEth increased caspase 3/7 expression 
the most in SW620 cells (by 46% against SW620). These results confirm that 
apoptosis appears to be triggered after BNIP treatment against CRC cell lines. 
The experiments would require to be repeated as it was a proof of concept that 
Caspase 3/7 level could be detected using this image cytometry system. 
BNIPPiEth has not been evaluated against SW480 due to a human error during 
analysis and the lack of material to repeat this experiment. Further optimisation 
regarding the dye incubation times and the cell concentration is required to 
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obtain better signals and more robust data. The recent application of the 
microplate reader – image cytometer is a promising option to achieve this 
objective since this new system allows high throughput tests using 96-well 
plates. Moreover, the fluorescent filters of the image cytometer allow the 
detection of acridine orange and propidium iodide which would make possible to 
also assess the cell viability.  
Image cytometry using the Cellometer (Nexcelom) appeared to be a promising 
and rapid way to screen different drug candidates on different cell lines in order 
to produce pilot study results and thus helping with the design of efficient future 
research projects. In this study, the use of the image cytometer was limited to 
the setup of the system and the exploration of its potential applications. However, 
apoptosis detection was successful using both Annexin V/PI and Caspase 3/7 
activity detections. Nevertheless, more robust data is needed to draw further 
scientific conclusions. Section 4.3.3. will provide a more robust apoptosis analysis 
via the detection of the caspase-3 protein.  
 
3.4.3. Effects of BNIPs on the cellular mechanisms of colorectal cancer 
cells leading to cell death 
 
Based on the preliminary results obtained using the new image cytometry 
system, the investigation of BNIPs mechanism of action has been further 
explored.  
Most of the chemotherapies leads to apoptosis due to their direct toxicity. For 
example, anti-cancer drugs can induce an increase in ROS and/or damage DNA 
leading to programmed cell death. More recently, many new drug candidates 
have been developed to target the activation of the apoptotic pathway itself such 
as Bcl-2 inhibitors (Bao et al., 2017). 
Regarding the cytotoxicity of BNIP derivatives, determining its mode of cell death 
is key to understanding the end point affected by the drug. Nonetheless, gaining 
a full understanding of the biological events happening between the cellular 
uptake of the drug and the resulting cell death will help the advancement of a 
BNIP-based chemotherapy.  
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There is strong evidence that chemotherapeutic agents can trigger the intrinsic 
pathway of programmed cell death by targeting the cytoskeleton, the synthesis 
of growth factors, the induction of DNA damage or the generation of oxidative 
stress (Claire et al., 2018). Previous studies have shown that BNIP derivatives 
have binding affinities to DNA leading to its damage in various cell lines but not 
yet in SW480 and SW620 (Brana et al., 1993; Brana et al., 2001; Barron et al., 
2010). Therefore, DNA damage was assessed using COMET assay alongside the 
associated generation of ROS. Moreover, the expression of 35 apoptosis-related 
proteins was carried out using the proteome profiler human apoptosis array and 
the detection of caspase-3 was also performed to corroborate the mode of cell 
death detected using image cytometry. 
 
3.4.3.1. Effects of BNIP derivatives on DNA damage in SW480 and 
SW620 cells assessed by COMET assay 
 
DNA damage can be induced by internal factors such as ROS or by external 
factors such as radiation or chemical agents (Turgeon et al., 2018). The main 
consequence of DNA damage is the modification of DNA structure via breaks in 
the nucleic acid chain or at the level of the phosphate backbone leading to 
alterations in the DNA metabolism (Chatterjee and Walker, 2018). These 
structural defects disrupting the normal cell metabolism can lead to cell death. 
In healthy cells, damaged DNA can be repaired using inherent mechanisms such 
as homologous recombination or nucleotide excision repair (Errol et al., 2006). 
Nevertheless, if the level of damage inflicted is too high, the repair mechanisms 
are not effective and DNA damage can lead to apoptosis (Wang, 2019). 
The COMET assay is a single gel electrophoresis assay (SCGE) for the evaluation 
and quantification of DNA damage. First developed by Ostling et al. (1984), the 
COMET assay consisted of the analysis of single cells embedded on agarose-
coated slide (Ostling et al., 1984). The cells were lysed while being trapped into 
the gel and, after electrophoresis and fluorescent staining using a DNA specific 
dye, the damaged DNA was separated from the intact DNA forming the “head” 
of a comet shape from the “tail” corresponding to the damaged DNA which has 
migrated through the gel (figure 22).  
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The analysis under fluorescent microscopy allows the identification of the level of 
damage as the extent of DNA forming the tail corresponds to the amount of DNA 
damage (Fairbairn et al., 1995). 
  
Figure 22. Fluorescent microscopy image of a COMET obtained after 
SW620 treatment with 200 µM H2O2 for 30 minutes.  
 
3.4.3.1.1. Optimization of the positive control concentration using 
hydrogen peroxide 
 
To induce consistent DNA damage and have a positive control for this 
experiment, hydrogen peroxide (H2O2) was used as it induces DSBs in cells 
(Benhusein et al, 2010). Many studies have used it as a positive control however, 
H2O2 concentration needs to be determined first for every experimental setup. 
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Figure 23. DNA strand breaks in SW620 induced by hydrogen peroxide 
determined by COMET assay. Data obtained after treatment using hydrogen 
peroxide (0 – 500 µM) for 30 mins on ice. The experiment has been performed 
in duplicate (A and B); n=2. 
 
H2O2 induced DNA damage at all of the concentrations that were tested from 50 
to 500 µM (figure 23). The experiment was repeated twice using two gels per 
experiment (n=2). For subsequent experiments, in both SW480 and SW620 cell 
lines, 200 µM H2O2 was used as positive control as it induced significant damage 
while 500 µM was considered unnecessary since, at 200 µM H2O2 concentration, 




3.4.3.1.2. The effects of BNIPs on DNA damage on colorectal cancer 
cells  
 
Both SW480 and SW620 cells were treated using BNIPDaCHM, BNIPPiProp and 
BNIPPiEth at IC25 for 24 hours to evaluate their effect on DNA damage. 
 
Figure 24. COMET Assay: DNA double strand breaks in SW40 and 
SW620 cells after a 24 hr-treatment using BNIP derivatives at their 
IC25. Hydrogen peroxide-induced DNA damage (200µM) has been used as 
positive control. Data are mean ± SD of 2 replicates from 3 independent 
experiments (n=3).  
 
First, figure 24 shows that the assessment of DNA damage was validated by 
having an average score below 20 for the negative control and with a significant 
increase of DNA damage for the positive controls (p<0.001) with similar scores 
for both cell lines. BNIPPiProp, BNIPDaCHM and BNIPPiEth showed significant 
increase in DNA damage (p<0.001) in both cell lines with scores ranging from 59 
to 121. The two cell lines tested, exhibited similar responses to the treatment. 
These results are concurring the results of Kopsida et al. (2018): the latter 
reported the induction of DNA damage by these 3 drugs against MDA-MB-231 
78 
 
and SKBR-3 breast cancer cells. Additionally, Barron et al. (2015) reported 
similar results for BNIPDaCHM in MDA-MB-231 cells. As highlighted in those 
studies, the proliferation rate of a cell line may affect its DNA stability, with the 
cells which have the highest replication rate, being more sensitive to DNA 
damage. Interestingly, this difference can be observed here with the results 
shown by the SW620 cell line. The latter exhibited an increased score in DNA 
damage of 20 to 40 compared to the SW480 cell line results for all of the three 
drugs (figure 18). Yeh et al. (2008) has shown the SW620 cell line to have a 
higher proliferation rate than SW480 due to its metastatic properties which could 
explain the increase in DNA damage observed here. However, the difference in 
scores was not statistically significant between the two cell lines. In relation to 
the drugs tested, significant differences in DNA damage scores were detected 
among the two breast cancer cell lines studied by Kopsida et al. (2018), 
demonstrating that different cells can behave differently and that further BNIP 
concentrations could be tested to see similar effects. In these CRC cells, similar 
effects of DNA damage were also observed with anticancer drugs, Oxaliplatin or 
Trifluorothymidine (Temmink et al., 2007).  
With BNIPs significantly inducing DNA strand breaks in SW480 and SW620 cells, 
it was then decided to continue the investigation with the potential mechanistic 
link between DNA damage and the generation of oxidative stress by reactive 
oxygen species. 
 
3.4.3.2. Determination of ROS levels after BNIP treatment  
 
ROS is a term that includes molecules, ions and free radicals derived from 
molecular oxygen which are highly reactive due to the single unpaired electron 
located on their most external electronic shell. At high levels, ROS can lead to 
cellular damage including DNA damage (Lori et al., 2008). Many anti-cancer 
drugs, such as physalin, have demonstrated the induction of apoptosis in cancer 
cells via the promotion of ROS signalling pathways (Kang et al., 2016). Therefore, 
the level of ROS generation of an anti-cancer drug is key to assessing its potential 
clinical translation (Gibellini et al., 2010). 
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ROS production, as a result of BNIP treatment, was assessed by fluorescence 
with CM-H2DCFDA dye. Both SW480 and SW620 cell lines were treated with the 





















































Figure 25. Relative percentage ROS levels in SW40 and SW620 cells 
after 24 hr-treatment with BNIP derivatives at their IC25 and IC50. The 
results are expressed as a ratio treatment/control (untreated cells) with control 
being 100% ROS level. Data are mean ± SD of from 3 independent 
experiments (n=3).  
 
After 24 hr-treatment, BNIPPiProp, BNIPDaCHM and BNIPPiEth all showed an 
increase in ROS production. However, only BNIPPiEth at IC25 significantly 
increased ROS levels in SW480 (p<0.01) and SW620 (p<0.001) cells (figure 25) 
whereas the other two drugs had no effect at that concentration. At IC50, all three 
drugs showed a significant increase in ROS production in both cell lines 
(p<0.001). For each cell line, BNIPPiEth (IC50) showed a greater induction of ROS 




The more stable the chemical structure is, the more difficult it is for the 
compound to undertake oxidation (Davasagaya et al., 2004). With the highest 
response obtained with BNIPPiEth, this difference can be explained by its 
chemical structure: it is the compound with the shorter linker chain (figure 3. 
section 1.2.2.). This particularity may result in the chemical instability leading to 
an increased ROS generation. 
This study has demonstrated the generation of ROS by BNIPDaCHM, BNIPPiEth 
and BNIPPiProp at their IC50 values (1.3 – 2.6 µM) after a 24-hour treatment 
against both SW480 and SW620 cells. Gold standard drugs such as Tamoxifen or 
Doxorubicin showed similar mode of action linking DNA damage to ROS 
generation which support the clinical relevance of BNIPs against CRC. Since ROS 
are increased by BNIPs, it is important to understand the link between ROS 
generation and the mode of cell death. 
 
3.4.3.3. Effects of BNIP derivatives on apoptotic cell death in SW480 
and SW620 cells assessed by Caspase-3 detection  
 
One of the first initiating events of apoptosis is the activation of the caspases 
which makes the detection of these proteins a key method in the mode of cell 
death investigation. As a mediator of apoptosis, caspase-3 has been the target 
of choice and this enzyme is responsible for the cleavage and activation of other 
caspases (6, 7 and 9). Thus, the detection of caspase-3 is directly linked to the 
programmed cell death pathway and is an important marker of apoptosis (figure 
7. section 1.4.2.).  
The chosen method for Caspase-3 detection was the Caspase-3/CPP32 
colorimetric Assay Kit. This method is based on the detection of p-nitroaniline or 
pNA. pNA is a chromophore which is conjugated to a specific sequence, an amino 
acid motif called DEVD. As an intracellular cysteine protease and once activated, 
Caspase-3 will specifically cleave the DEVD sequence which allows pNA to be 
detected using spectrophotometry detection at 405 nm. The level of the Caspase-
3 activity is then directly proportional to the quantity of pNA released.  
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Here, caspase 3 activity in SW480 and SW620 cells has been investigated after 




Figure 26. Detection of caspse-3 level in SW480 and SW620 cells after 
a 24 hr-treatment using BNIP derivatives at their IC25. Data are mean ± 
SD of 6 replicates from 3 independent experiments (n=3).  
 
The results in figure 26 showed that, when compared to control, there was no 
significant increase in the detection of caspase-3 after treatment with any of the 
three drugs at their respective IC25 concentrations (0.75 - 2.1 µM). Of note, the 
results obtained were consistent between the two cell lines. However, treatment 
with BNIPPiEth exhibited a significant decrease (p<0.01) in caspase-3 compared 
to the control only in SW620 cells, implying a potential chemoresistance of 
SW620 for BNIPPiEth.  
Taking together all of the preliminary data obtained using image cytometry, 
apoptosis appeared to be a potential mode of cell death induced by BNIP 
derivatives. The results exhibited in figure 26 showed that apoptosis was not 
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observed after a 24 hr-treatment using the BNIP derivatives against SW480 and 
SW620. 
The use of the 24 hr-time point at the IC25 concentration of the BNIP derivatives 
implied that cell death was occurring, having previously observed a decrease of 
cell viability with MTT assay. However, the detection of apoptosis using caspase-
3 relies on the detection of this particular protein. The commercial kit used in this 
experiment will only detect the active form of caspase-3 in the cell lysate and not 
the inactive procaspase-3. Therefore, the evaluation of caspase-3 activity would 
be useful to confirm the absence of apoptosis. The chosen 24 hr time point might 
be too long for an effective apoptosis detection using this test; a range of time 
points should be investigated to confirm these findings.  
 
3.4.3.4. Effects of BNIP derivatives on protein expression in SW480 and 
SW620 cells assessed by human apoptosis array 
 
Protein array technology was used to further explore molecular mechanisms 
associated with apoptosis and which could be affected by cells treatment with 
BNIP derivatives. 
The proteome profiler human apoptosis kit allows the simultaneous detection of 
35 apoptosis-related proteins in the cell lysate. This membrane-based sandwich 
immunoassay (figure 27) was used on both SW480 and SW620 lysate after a 24 





Figure 27. Picture of an X-ray film after exposure to a treated array 
membrane (BNIPPiEth) with the associated spot coordinates, with each 




Table 5. List of proteins detected by the human apoptosis array with 








































































































































































Figure 28. Relative expression of proteins expressed by SW480 and 
SW620 cells treated with BNIPPiProp, BNIPDaCHM and BNIPPiEth at IC25 
concentrations for 24 hrs. Results expressed as ratio treatment to control for 
proteins with ratio >2 or <2 Experiments performed in duplicate. 
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With the SW480 cell line, 3 proteins were upregulated (figure 28) presenting a 
ratio to control of 2.0 or more. Pro-caspase-3 were found to be upregulated after 
treatment with the 3 drugs. TNFRI/TNFRSF1A were upregulated only using 
BNIPPiEth and P21/CIP1/CDK1N1A only after treatment with BNIPPiProp. Six 
proteins were found to be downregulated (figure 28) showing a ratio treatment/ 
control below -2. All six proteins were downregulated by BNIPPiProp. Phospho-
p53 and HSP60 were highly downregulated with ratio between -5 and -15 and 
they were the only two proteins downregulated by all the drugs. Finally, Bcl-x 
was downregulated by both BNIPPiProp and BNIPPiEth.   
On the other hand, with the SW620 cell line, 9 proteins were found to be up 
regulated (Pro-Caspase-3, Cleaved-Caspase-3, Catalase, cIAP-2, Clusterin, 
Cytochrome c, HSP60, Livin and XIAP). The treatment using BNIPDaCHM induced 
more greater changes with 7 proteins upregulated. Moreover, these 
upregulations are unique to the treatment of BNIPDaCHM (exception of HSP60 
also upregulated). XIAP was only up regulated by BNIPPiEth and pro-caspase-3 
was upregulated by BNIPPiProp and BNIPPiEth but down regulated by 
BNIPDaCHM. Interestingly, between the two cell lines, pro-caspase-3 is the only 
protein that has been found to be upregulated in both cases. Moreover, HSP60, 
which is downregulated in SW480, is upregulated in SW620.  
The vast majority of the protein detected were not affected by the BNIPs (ratio 
treatment/control between -2 and 2) with no change in their expression level 
compared to the untreated control.  
Starting with SW480, the only two proteins that were upregulated were TNFR1 
and p21. TNF R1 or tumour necrosis factor receptor 1 is a tumour membrane 
receptor which mediates apoptosis. Once bonded with TNF-alpha, TNFR1 recruits 
the death domain protein TRADD at the intracellular level which results in the 
activation of the caspase cascade (Baud and Karin, 2001). Only BNIPPiEth has 
presented an upregulation of TNF R1 in SW480. Even if related to apoptosis 
mediation, the detection of this protein alone is not directly linked to an increase 
in apoptosis but potentially to an increase in the expression of the membrane 




The p21 protein, known as cyclin-dependent kinase inhibitor p21, is a 
proliferation inhibitor causing cell cycle arrest and is involved in the prevention 
of tumour development. For example, human cancer cell lines treated with 
alkylating agents saw their cycle arrested by the action of p21. The cleavage of 
p21 then led to apoptotic death (Zhang et al., 1999). Barron et al. (2010) showed 
that BNIPDaCHM induced DNA damage and repaired instability in triple negative 
breast cancer cells via p21 expression. 
Pro-caspase-3 is the non-cleaved or inactivated form of caspase-3. Once 
activated, the resulting proteolytic cascade leads to the amplification of the 
apoptotic signalling pathway. The upregulation of pro-caspase-3 was found in 
both cell lines. 
Phospho-p53 (S392) corresponds to the p53 transcription factor phosphorylated 
at serine 15. S392 corresponds to Serine 392 which is the phosphor-acceptor site 
located in the C-terminal regulatory domain (Hupp et al., 1995). This specific 
phosphorylation enhances the DNA-binding properties of p53. This enzyme is 
known as a tumour suppressor reacting to diverse stress signals to deliver 
antiproliferative responses. More precisely, one of its main function is the 
activation of programmed cell death in a transcription-dependant manner 
(Fridman and Lowe, 2003). The inhibition of p53 action causes tumour promotion 
and chemoresistance. Here, the protein has been highly downregulated in SW480 
but not in SW620. Additionally, previous research has already linked the 
activation of p53 to the treatment with BNIP derivatives in cancer cell lines (Li et 
al., 2012; Liang et al., 2011). 
Bax, Bcl-2 and Bcl-x are three mitochondrial proteins. They mediate apoptosis 
via the regulation of the liberation of cytochrome c from mitochondria which lead 
to the activation caspase and ultimately to programmed cell death (Korsmeyer, 
1995). The 3 proteins were found to be downregulated by BNIPPiProp alone in 
SW480. Jiang and Milner (2003) has shown that the downregulation of this family 
of proteins resulted in the induction of apoptosis in glioblastoma cells. Moreover, 
BNIPPiProp was found to down regulate cytochrome c in SW480 alone confirming 
the mediation of apoptosis. Interestingly, the HSP60 protein is downregulated in 
SW480 but upregulated in SW620. The heat-shock protein 60 (HSP60) is a 
mitochondrial protein which is used as a danger signal for stressed or damaged 
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cells and prevents protein aggregation that can often occur during stress 
(Wiechmann et al., 2017). Based on these results for SW480, the down-
regulations of a majority of pro-apoptotic factor can indicate that apoptosis is not 
the node of cell death observed using BNIPPiProp, BNIPDaCHM and BNIPPiProp 
corroborating the previous data obtained with caspase-3 detection. However, the 
up-regulation of pro-caspase-3 may suggest the presence of another regulated 
mode of cell death such as autophagy.  
In SW620, 7 proteins were upregulated by BNIPDaCHM only including Cleaved-
Caspase-3, Catalase, cIAP-2, Clusterin, Cytochrome c, HSP60 and Livin. The 
upregulated proteins are found to be factors inhibiting apoptosis. The cellular 
inhibitor of apoptosis 2 (cIAP2/HIAP1) is a strong inhibitor of apoptosis. 
Moreover, catalase is a H2O2 specific scavenger which is known to reduce 
apoptotic levels after the use of drugs such as etoposide, camptothecin or 
doxorubicin (Sancho et al., 2003). Additionally, Livin is also an inhibitor of 
apoptosis inhibiting caspase activity (Kasof and Gomes, 2001), and Clusterin, 
when overexpressed, protects the cell from apoptosis induced by chemotherapy 
(Koltai, 2014). The upregulation of all of these factors leads to the conclusion 
that BNIPDaCHM induced an inhibition of apoptosis in SW620. However, the 
upregulation of cytochrome c and of the caspase-3 proteins showed that there 
was a simultaneous promotion of apoptotic cell death. This implies that SW620 
might be exhibiting a specific drug resistance to BNIPDaCHM. Luo et al. (2016) 
has previously shown that there is greater ability of drug resistance in metastatic 
cells SW620 than in primary SW480 supporting this data.  
Therefore, the results obtained with the proteome profiler array, showed the 
presence of heterogeneity on drug resistance between SW620 and SW480 cell 
line. Moreover, the differences in the mechanism of action of the 3 drugs can be 
clearly observed. Together, these findings provide a first indication of the 
complexity of the BNIP mechanism of action relating to cell death by exhibiting 
a different pattern depending on the type of cell line, experimental conditions 
and the drug tested. Interestingly, studies have studied apoptotic signalling 
pathways and demonstrated the existence of crosstalk between the different 
mode of cell with for example autophagy and this have been discussed further in 














4.1. General discussion   
 
The use of solid lipid nanoparticles for the encapsulation of BNIPPiProp was 
limited by the drug delivery system cytotoxicity in SW480 and SW620 CRC cell 
lines. 
In chapter 2, the encapsulation of BNIPPiProp into solid lipid nanoparticles has 
been performed. This technology developed in 1991 by Müller is promising by 
being at the interface of liposomes and polymeric nanoparticles (Corrias and Lai, 
2011). They have been extensively studied for a wide range of biomedical 
applications ranging from drug and gene delivery to diagnostic tools (Yang et al., 
2016). The SLNs were successfully manufactured offering physico-chemical 
properties matching the standards of chemotherapy drug delivery systems with 
an average size of 150 nm, associated with a PDI of 0.2, and a negative zeta-
potential below -20 for the selected batch Ae. However, the low encapsulation 
efficiency (<1%) obtained for BNIPPiProp encapsulation coupled with the high 
cytotoxicity observed with the empty nanovectors against both SW480 and 
SW620 colon cancer cell lines, questions this formulation’s suitability and needs 
further investigation. 
The cytotoxicity of the empty nanocarrier can be potentially linked to the 
presence of surfactants as stearic acid has be reported to be non-cytotoxic 
(Thakkar et al., 2016). The original using this combination of surfactants did not 
assess its cytotoxicity (Aditya et al., 2014). Regarding manufacture, the hot 
homogenisation method has been reliable with a good batch-to-batch 
reproducibility. Moreover, this method did not require sophisticated equipment 
while avoiding the use of organic solvents. This represents a unique opportunity 
to design a scalable drug delivery system production at a reasonable cost 
(Marengo et al., 2000). First, the determination of the origin of the toxicity should 
be investigated and it is usually performed by replacing components of the 
nanoparticles such as the surfactants. Although, batch Ae was selected as the 
candidate for the in vitro study, different formulations were manufactured with 
the use of PEG stearate creating different lipid/surfactants combinations. 
Therefore, the other empty formulations should firstly be tested against both cell 
lines to observe potential changes in the cytotoxicity profile. 
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On the other hand, to improve the loading efficiency of BNIPs inside SLNs which 
was still limited (<1%), changes in the drug/lipid ratio could also lead to an 
increased drug loading. Offering a mix of lipid to the solid core of the nanoparticle 
could lead to the creation of more imperfections allowing more drug to be 
encapsulated. If the presented solutions remain unsuccessful, the use of NLCs 
could also be investigated as its liquid lipid core could be more suited for the 
encapsulation of BNIPs.    
Further characterisation of the SLNs would also be beneficial to obtain a better 
understanding of the impact of formulation changes. The evaluation of the 
stability, the release profile and also the use of differential scanning calorimetry 
would provide more information to compare the different batches and to assess 
how the incorporation of the drug impacts the nanoparticles (Campos et al., 
2020). For example, determining if the encapsulated drug is in an amorphous or 
crystalline state within the particle core would give an indication of its degree of 
solubility in lipids leading to key formulation adjustments.   
Although early in its development, it is also important to discuss the translation 
of the in vitro study of BNIP drug delivery systems to an animal model. While the 
EPR effect is an essential mechanism for the delivery of chemotherapy, 2D in 
vitro assessment of its benefits can be difficult due to the inner limitations of cell 
culture systems. More physiologically relevant models have been developed 
including the use of 3D cell culture platforms using for example the growth of 
cancer cells on 3D hydrogel scaffolds which could be more relevant for further 
studies (Shi et al., 2016). 
A previous study by Costa Lima et al. (2012) reported an attempt to encapsulate 
BNIP derivatives inside pegylated PLA nanoparticles with an associated in vitro 
study against Leishmania infantum protozoa. The PLA nanoparticles exhibited an 
encapsulation efficiency of more than 80%. The low encapsulation efficiency 
(<1%) obtained for BNIPPiProp encapsulation coupled with the high cytotoxicity 
observed for the empty nanovectors against SW620 and SW480 has been a 
drawback in the development of a drug delivery system for BNIP derivatives.  
However, obtaining a better understanding of the drug’s cellular mechanism of 
action represented the next step to refine the design of SLNs to produce a tailored 
drug delivery system targeting CRC. The development of targeted nanoparticles 
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specific to CRC therapy can be achieve by the grafting of antibodies peptides or 
aptamers to functionalized the surface of the nanoparticles (Cisterna et al., 
2016). For example, poly(D,L-lactic-co-glycolic acid)-block-polyethylene glycol 
nanoparticles encapsulating cisplatin were formulated and a integrin-receptor 
specific cyclic pentapeptide  were added to the drug carrier surface to bind to this 
CRC overexpressed receptor (Graf et al., 2012).  
The design nanoparticle drug delivery systems for the delivery of BNIPs is still at 
an early stage but this study presented the opportunities associated with the use 
of lipid based-carriers. Subsequent discoveries of the BNIP mode of action 
reported in this project are important information which could lead to the 
formulation of more tailored nanomaterials for the delivery of BNIPPiProp, 
BNIPDaCHM and BNIPPiEth to treat CRC. 
 
BNIPPiProp, BNIPDaCHM and BNIPPiEth demonstrated strong cytotoxicity against 
SW480 and SW620 CRC cell lines. 
 
Without being encapsulated, BNIPPiProp, BNIPDaCHM and BNIPPiEth all showed 
strong cytotoxicity against both cell lines with IC50 values ranging from 1.3 to 2.6 
µM. As previously stated, these IC50 values are much lower than the ones 
obtained using the most common chemotherapy agents against CRC. Moreover, 
BNIPPiProp, BNIPDaCHM and BNIPPiEth also appeared more cytotoxic than 
previous version of BNIP derivatives. For example, amonafide presented an IC50 
of 4.67 μM and BNIPOSpm, >50 µM, against HT-29 CRC cell line. This comparison 
shows the success of the formulation of the latest generation of BNIPs with the 
design of the linker chain leading to an increased cytotoxicity against CRC in 
vitro. 
The MTT assay is considered as the gold standard for cell viability assessment 
since the 1980s (Mosmann, 1883). However, the scientific community has 
reported several challenges associated to its use. MTT relies on the metabolic 
activity of living cells to produce formazan, however endogenous and exogenous 
compounds can also be the initiator of this change (Hansen et al., 1989; Zhang 
et al., 1990). The choice of a cell viability assay needs to be rationalised based 
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on the sensitivity of the test allowing the detection of the cell viability variation 
with a good reproducibility under controlled experimental conditions (Tonder et 
al., 2015). Alternative assays can be chosen with for example the use of the 
Resazurin reduction assay (McMillian et al., 2002) or the sulforhodamine B assay 
(Rubinstein et al., 1990). A comparative study performed by Tonder et al. 
(2015), demonstrated that the MTT assay presented the highest variability due 
to interferences with compounds tested compared to the two other methods. 
However, in the case of this project, MTT assay remained the most time- and 
cost-effective choice for the determination of BNIPs cytotoxicity and it also 
provided a unique and reliable way to compare the IC50 values determined from 
this study to previous generations of BNIPs tested in the past. The extension of 
the BNIP exposure time (>24 hrs) would provide interesting data to assess a 
change in the cytotoxic profile of the BNIPs, allowing the determination of IC50 
values for different time points for future experiments. The incorporation of 
commercially available colorectal cancer anti-cancer drugs in the cytotoxicity 
testing would also be a great addition to obtain a direct comparison of the 
cytotoxicity of BNIPs against the current chemotherapy gold standards. This well-
studied control could then be kept throughout the in vitro study to show an 
internal control for the drugs’ mechanism of action investigation.  
With the 3 drugs showing the same cytotoxicity pattern on both cell lines, the 
use of BNIPPiProp, BNIPDaCHM and BNIPPiEth appeared to be clinically relevant 
for the treatment of CRC and could potentially lower the chemotherapy side 
effects by requiring a much lower dose.  
 
BNIPPiProp, BNIPPiEth and BNIPDaCHM generated a >50% increase of ROS 
levels and provoked DNA double strand breaks in SW480 and SW620. 
 
The generation of ROS after treatment with anticancer drugs caused the 
accumulation of ROS within the cells which preceded oxidative stress and 
eventually cell death via apoptosis or terminal differentiation (Watson et al., 
2011). Moreover, ROS are considered as mediators of DNA damage contributing 
to the genotoxicity of chemotherapeutic drugs such as cisplatin or doxorubicin 
(Conklin, 2004). More generally, anthracyclines, alkylating agents and platinum 
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complexes are ROS generators which interfere with cellular events such as cell 
cycle progression and apoptosis (Mizutani et al., 2005). For example, the 
synergistic effect of oxaliplatin with piperlongumine has been proven to be ROS-
mediated against human HCT-116 and LoVo cells (Chen et al., 2019). 
Additionally, the study of Cheng et al. (2015) showed that the combined use of 
oxaliplatin and piperlongumine increased ROS levels and also triggered 
endoplasmic reticulum stress which led to the activation of the ER stress-specific 
apoptotic cascade protein CHOP leading to apoptosis (Cheng et al., 2019).   
Here, the reported generation of ROS associated with the induction is a major 
finding that contributes to the elucidation on the mechanism of action of BNIPs. 
BNIPPiProp, BNIPDaCHM and BNIPPiEth all induced more than a 50% increase of 
ROS levels against both SW620 and SW480 after a 24 hr-treatment at IC50 
concentrations. In this study, the CM-H2DCFDA dye was used which became 
fluorescent after oxidation, allowing us to assess the ROS levels in vitro. The use 
of a positive control such as H2O2, PMA (4beta-phorbol, 12-myristate, 13-
acetate) and tert-butyl hydroperoxide (TBHP) could also be employed in future 
experiments.  
As CRC cells generates higher basal ROS levels than regular cells, the important 
increase of ROS produced after BNIP-treatment can be responsible for cancer cell 
death (Lin et al., 2018). ROS generation can be initiated in two major ways: the 
mitochondrial ROS generation or the inhibition of the antioxidant protective 
system (Yang et al., 2018). Drugs such as arsenic trioxide (Shi et al., 2004) or 
Doxorubicin (Marullo et al., 2013) targeted the mitochondria to induce ROS 
generation whereas Imexon (Dragovich et al., 2007) or Mangafodipir (Alexandre 
et al., 2006) regenerated the reduced form of antioxidants. Therefore, 
determining more precisely the cellular mechanism behind the BNIP-induced ROS 
generation can be interesting to explore in greater detail the mechanism of action 
of these drugs compared to other anti-cancer drugs. The generation of ROS can 
also participate to the reduction of multi-drug resistance with the example of 
piperlongumine which increase the expression of p53 in SW620 due to the 
induction of oxidative stressed. Combined with doxorubicin, the therapy 
demonstrated a greater anti-cancer potential increasing the drug sensitivity via 
the production of ROS (Basak et al., 2016). Consequently, the BNIP-induced 
generation of ROS levels is particularly promising for the treatment of late stage 
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CRC even if no significant differences were observed between SW480 and SW620 
here.  
In addition to the generation of ROS, COMET assay revealed that BNIPPiProp, 
BNIPPiEth and BNIPDaCHM were found to significantly augment DNA DSBs in 
both SW480 and SW620 using IC50 concentrations. These findings showed that 
the BNIP treatment led to genomic instability in both cell lines. However, no 
significant differences were observed between them as it could have been 
expected due to the higher proliferation rate of SW620 often associated with 
more DNA damage induced. As with ROS generation, DNA damage can be 
observed during chemotherapy-induced cell death (Borges et al., 2009). These 
two events can be found independently or associated, with one caused by the 
other one. For example, the use of Actinomycin D creates single and double 
strand breaks with an associated increase of ROS levels (Wang et al., 2007). 
Furthermore, ionizing radiation can cause both DSBs and hydroxyl radical 
formation (Hall et al., 1973). Interestingly, previous studies on BNIPDaCHM, the 
parental compound of BNIPPiProp and BNIPPiEth, proved the induction of DSBs 
and the inhibition of DNA repair in triple negative breast cancer cells (Barron et 
al., 2015). Here, the significant increase of ROS and DSBs in both cell lines using 
BNIPDaCHM, BNIPPiProp and BNIPPiEth is a key component to explain the 
cytotoxicity of these compounds.  
Barron et al. (2015) also showed that BNIPDaCHM was capable to inhibit DNA 
repair in triple breast cancer cell lines. Two mechanisms for the repair of double 
DNA strand breaks can occur, namely the homologous recombination and the 
non-homologous end-joining (Rasool et al., 2007). These mechanisms play a 
fundamental role as they can be the source of chemotherapy resistance 
(Murugesan et al., 2017). Demonstrating a significant change of DNA repair 
levels between the two cell lines after treatment using the BNIPPiProp, 
BNIPDaCHM and BNIPPiEth would need to be further explored as it would offer a 
viable option to treat chemo-resistant cancer. 
With no significant differences observed between the 3 drugs in terms of 
cytotoxicity, ROS generation or DNA damage induction, no conclusion can be 
made regarding their relative potency making them all strong candidates in the 
treatment of CRC. The use of more time points in the study of their mechanism 
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of action could provide interesting data regarding the potential impact of the 
molecular structural differences of the 3 drugs which might not be perceived after 
24 hours. Additionally, the study of the cellular drug uptake would allow the 
determination of a more precise time frame for biochemical assays.  
With the determination of low IC50 values using MTT assay, the evaluation of the 
mode of cell death appeared critical as many drug discovery strategies focus on 
the molecular targets of the drugs associated with cell death or the disruption of 
cell cycle. Although other regulated mode of cell death such as autophagy or 
necroptosis are known to be linked to the action of anti-cancer drug (Portt et al., 
2011), the detection of ROS generation and DNA damage induction by 
BNIPPiProp, BNIPDaCHM and BNIPPiEth firstly led to the investigation of 
apoptosis as proposed mode of cell death.  
 
The use of BNIPPiProp, BNIPPiEth and BNIPDaCHM revealed the existence of a 
drug- and cell line- dependant complex regulated mode of cell death in CRC 
SW480 and SW620 cell lines. 
 
First, a pilot study using image cytometry was performed to obtain first evidences 
indicating the induction of apoptosis by BNIP derivatives. In recent years, the 
use of image cytometry has been developed due to the technical improvement 
of these systems meeting clinical accuracy requirements (Lohman et al., 2018). 
For example, the use of image cytometry included the detection of circulating 
tumour cell detection in hepatocellular carcinoma (Liu et al., 2016). 
The results obtained with the caspase-3 detection showed no differences between 
the caspase 3 level of untreated cells and treated cells by the BNIPPiProp, 
BNIPPiEth and BNIPDaCHM at IC25 concentration for 24 hours. This assessment 
did not corroborate the first evidence obtained using image cytometry. Further 
experiments should be performed to evaluate if this absence of apoptosis 
detection can be due to an inaccurate time-point of analysis. Moreover, the 
expression of caspase-3 can be specific to tumour type and the activity level of 
this protein could change during upon the cancer stage (Fujikawa et al., 2000; 
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Grigoriev et al., 2002). Therefore, emerging therapies are looking at targeting 
caspase-3 to induce apoptosis in cancer cells (Hu et al., 2020). 
Subsequently, this result was challenged by the human apoptotic array analysis 
which provided a deeper insight into the mode of cell undertaken by SW480 and 
SW620 after BNIP treatment.  
Using the human apoptosis array, a more global picture of the impact of BNIPs 
on the complex apoptotic pathway was obtained. As this experiment was only 
perform in duplicate, the major trends were discussed. Among the 35 apoptotic-
related proteins detected, pro-caspase-3 was the only protein which was found 
to be upregulated in both SW480 and SW620. Although pro-caspase-3 is the 
inactive form of caspase-3, this result is particularly promising as the leveraging 
of pro-caspase-3 overexpression is currently a molecular target for selective 
anticancer therapy (Boudreau et al., 2019). As most of the current cytotoxic 
compounds trigger apoptosis by affecting molecules upstream of pro-caspase-3, 
the direct upregulation of caspase-3 induced by BNIPs can represent a strategy 
to overcome apoptotic evasion and chemoresistance (Baig et al., 2016). For the 
moment, this strategy requires the synergistic use of a combination of anti-
cancer drugs such as temozolomide with procaspase activating compound 1 
capable of activating the overexpressed pro-caspase-3. The resulting treatment 
allowed the activation of the overexpressed protein to induce a stronger 
apoptosis response and this could be explored using the BNIPs (Joshi et al., 
2017). Consequently, the ubiquitous detection of pro-caspase-3 upregulation can 
be an indicator of the stimulation of the apoptotic pathway in both cell lines using 
the 3 compounds. Nevertheless, the validation of the overexpression of pro-
caspase-3 should also be validate using ELISA prior to further studies.  
More specifically in SW480, both phospho-p53 and HSP60 were found greatly 
down-regulated (from -5 to -15) indicating the absence of apoptosis as previously 
showed with caspase-3 detection.  
The second important trend showed by the array analysis was the upregulation 
of several apoptosis-inhibiting factors by BNIPDaCHM specifically against SW620. 
BNIPDaCHM appeared to have a greater impact on the regulation of the 
apoptosis-related proteins analysed which suggested that BNIPDaCHM had more 
impact on the cell death machinery of metastatic CRC.  
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Interestingly, the simultaneous regulation of pro- and anti- apoptosis factors also 
indicated that a complex cell death pathway regulation is taking place which could 
involve crosstalk between the apoptotic and autophagic modes of cell death. 
Additionally, an increasing number of studies showed the existence of alternative 
caspase-independent forms of programmed cell death which could potentially be 
occurring here. Therefore, the results presented related to the investigation of 
apoptosis as BNIP-induced mode cell death revealed the existence of a complex 
regulation potentially involving several pathways. These findings suggest that 
the mode of cell death induced by BNIPPiProp, BNIPPiEth and BNIPDaCHM 
remains undetermined and more specific studies exploring autophagy or 




4.2. Conclusion  
 
In this study, a solid lipid nanoparticle drug delivery system has been formulated 
to overcome the current limitations of BNIP derivatives for their delivery in CRC 
cells. Stearic acid-solid lipid nanoparticles were manufactured and the 
encapsulation of BNIPPiProp was performed (>1% drug loading). The 
development of the BNIP nanotherapeutics was hindered by the cytotoxicity of 
the empty nanocarrier against SW480 and SW620 cell lines. The cytotoxicity 
study revealed that the native 3 drugs BNIPPiProp, BNIPDaCHM and BNIPPiEth 
were strongly cytotoxic against both CRC cell lines after 24 hours (IC50 0.75 - 
2.60 µM). From there, the mechanism of action of BNIP derivatives was further 
elucidated. After a 24 hr-treatment, all 3 drugs showed an increase in ROS levels 
(>50%) and a significant creation of DNA double strand breaks assessed via 
COMET assay. The mode of cell death was also investigated. For the first time, 
image cytometry was used to screen the 3 compounds for apoptotic cell death. 
A more robust apoptotic cell death detection was then performed using a 
caspase-3 detection kit, however, no significant changes after treatment were 
noticed. Nevertheless, the proteome profiler array showed the upregulation and 
down regulation of a total of 16 different apoptotic-related proteins. BNIP 
derivatives appeared to regulate apoptotic factors in a cell line- and drug- 
dependant manner and suggests the existence of crosstalk between cell death 
pathways. Taken together, these findings showed the clinical relevance of 
BNIPPiProp, BNIPPiEth and BNIPDaCHM in the treatment of CRC. This study has 
improved the understanding of the BNIP mechanism of action against CRC which 
will help to design novel anti-cancer drugs and associated tailored drug delivery 
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